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Abstract
For patients receiving radiation therapy, there is a risk of developing radiation induced
carcinomas, especially if they have a long life expectancy. However, radiotherapy is not the
only contributor of radiation exposure to healthy tissue. With the introduction of highly
conformal treatment techniques comes the increase in pretreatment imaging necessary to
accurately target tumour volumes and consequently, radiation exposure to healthy tissue.
In this work the radiation dose delivered to radiosensitive organs from a number of
treatment planning techniques was evaluated and the risk of radiation induced cancer was
assessed. MOSFET detectors and Gafchromic film were used to measure the accumulative
concomitant dose to the thyroid and contralateral breast from early stage breast carcinoma
radiotherapy and to the contralateral testis from seminoma radiotherapy, with dose contribu-
tions from CT imaging for treatment planning, pretreatment imaging (CBCT) and treatment
delivery peripheral dose. To the author’s knowledge this is the first work investigating the
total concomitant treatment related dose and associated risk to these treatment sites.
Peripheral dose contributed the largest concomitant dose to the healthy tissue, measuring
up to 0.7, 1.0 and 5.0 Gy to the testis, thyroid and contralateral breast, respectively. The
highest testicular, thyroid and contralateral breast carcinoma risk was found to be 0.4, 0.2
and 1.4%, respectively.
In conclusion, the risk of radiation induced carcinoma to the assessed radiosensitive
tissues was found to be minimal, however, when considering treatment techniques and/or
introducing pretreatment imaging protocols, the dose to the normal tissue should be kept as
low as reasonably achievable.
Chapter 1
Introduction
Modern treatment techniques are capable of delivering highly conformal dose to target vol-
umes and rely on image guidance to accurately target the tumour volumes. Inevitably,
radiation is unintentionally delivered to normal tissue in the surrounding regions. This ra-
diation dose comprises of scatter from within the patient, collimation scatter and radiation
leakage through the head of the treatment machine and is herein collectively referred to as
peripheral dose. Additionally, healthy tissue will receive dose contributions from beam en-
trance and exit dose, planning CT and pretreatment imaging. Dose to tissue from diagnostic
medical exposure is in the order of mGy; e.g., 24 mSv for a chest Cone-beam CT (CBCT)2
and 30 mGy for a adult chest CT scan3, while from radiotherapy, healthy tissue can receive
dose in the order of Gy4,5.
The improving prognosis of radiation therapy is increasing the longevity of patients and
thus the time in which treatment related side effects can occur. The risk of radiation inducing
cancer is known from studying survivors of atomic bombs6,7 and other incidences involving
radioactive materials, e.g. Techa River8. More recently, the link between radiation exposure
for medical purposes and cancer induction has been investigated7,9.
An increased incidence of cancer, such as leukaemia10, lung11 and breast12 to name a
few, has been observed amongst patients who have received previous radiotherapy treat-
ment compared with the general population. Furthermore, the associated incidence is age
dependent and is greater for patients exposed at a younger age12,13. This correlation is not
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limited to therapeutic doses. Brenner et al.14 suggested that approximately 1.5% to 2.0%
of all cancers in the United States may be related to the radiation dose from CT studies.
Similarly, Berrington de Gonza´lez et al.15 estimated that approximately 2% of the cancers
diagnosed every year in the United States could be CT related.
An increased incidence of contralateral testicular cancer16,17 and a reduction in sperm
count18 has been observed following radiotherapy for testicular seminoma and consequently,
the dose to the contralateral testis is of concern. This dose has been investigated previously
using thermoluminescent detectors19 and several authors advocate the use of gonadal shield-
ing to reduce the dose to the contralateral testis19,20. Similarly, the dose to the contralateral
breast from breast carcinoma radiotherapy has been investigated21–24 and the associated sec-
ond cancer risk assessed. Additionally, the dose to the contralateral breast from diagnostic
imaging (CBCT) has been measured using an ionisation chamber25. Although treatment
and imaging related dose has been studied independently, to the author’s knowledge, the
total concomitant treatment related dose and subsequent secondary cancer risk has yet to
been investigated.
The aim of this work is to assess the radiation induced cancer risk as a result of the
total concomitant treatment related dose. The concomitant dose to the thyroid and con-
tralateral breast from early stage breast radiotherapy and the dose to the contralateral testis
from seminoma radiotherapy were measured using MOSFET detectors and Gafchromic film.
Additionally, dose contributions from treatment related CT and Cone-beam CT (CBCT)
imaging are considered.
In Chapter 2, the suitability of MOSFET and Gafchromic film for measuring these doses
is discussed. Chapter 3 details the risk models used to assess the dose related second cancer
risks. The seminoma and breast cancer case studies are presented in Chapters 4 and 5,
respectively, with the overall findings discussed in Chapter 6.
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Chapter 2
Dosimetry
2.1 Introduction
The amount of radiation dose healthy tissue receives during diagnostic imaging or radiation
treatment should be kept as low as reasonably achievable to reduce normal tissue compli-
cations, without compromising treatment intent. This dose is often measured via phantom
simulations26 or in clinical settings27, to ensure safe practice, using dosimeters, such as, ion
chambers, thermoluminescent detectors (TLD)26–28, MOSFETs29,30 and more recently, ra-
diochromic film31. In this work, MOSFET detectors and two types of radiochromic film were
used to measure peripheral surface dose from megavoltage treatment beams and surface dose
from kilovoltage imaging beams. The suitability of these dosimeters is discussed.
2.2 Gafchromic Film
2.2.1 Introduction
Gafchromic film (International Speciality Products (ISP), Wayne, NJ) is a type of self de-
veloping radiochromic film, which since it’s introduction in 2004, is gaining popularity as a
suitable dosimeter in radiology32–34 and radiation oncology35–37 applications. Unlike tradi-
tional film, it is self processing and does not require handling in a dark room. Gafchromic
film is versatile; it can be easily cut, immersed in water38 and handled in room light39. In
3
this work two types of Gafchromic film were used to measure dose from imaging modalities
and radiotherapy; XR-QA2 and EBT2, respectively.
EBT2 Gafchromic
EBT2 Gafchromic film was designed for use in the energy range 50 kiloelectron volt (keV)
into megavolt (MV) and with sensitivity down to 1 cGy. The upper dose limit is 10 Gy if
measuring in the red channel.1. It is near tissue equivalent (zeff= 6.84), has high spatial
resolution and exhibits weak energy dependence40. The film contains an active layer (Figure
2.1) with particles that polymerise and turn blue when exposed to ionising radiation. A
yellow marker dye is incorporated into the active layer of the film which protects the active
component from exposure to visible and UV light. Additionally, the dye can be used to
improve dose accuracy, if measured on a colour scanner, by applying corrections for the
non-uniformity in the film thickness.
Figure 2.1: The composition of EBT2 Gafchromic film1.
The film is digitised on a flatbed scanner39,41,42 and the absorbed dose is determined
by analysing the optical density of the film with respect to dose. The greatest uncertainty
in the dose measurements is due to the scanning technique used, however, this can be
reduced significantly if a rigorous scanning protocol is adhered to42–44. The film continues
to darken over time after irradiation and the darkening behaviour is dose dependent42,44.
To overcome this, it is recommended that the post irradiation scan time of the calibration
and measurement films be kept consistent. Devic et al.45 showed that a 1% dose error
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can be achieved if a scanning window of ±2h is employed for a 24h post irradiation scan
time. The uniformity of the scanner factors into the film response; differences of up to
5.5% have been reported depending on the position of the film on the scanner bed42. The
orientation of the polyester substrate layer (i.e., facing towards or away from the glass) has
little effect on the optical density for doses higher than 1 Gy (less than 1%)39. Alternatively,
scanning in the portrait orientation produces variations of up to 9%39. In this work, a strict
scanning protocol relating to film position, orientation and post irradiation digitisation time
was maintained.
XR-QA2 Gafchromic
XR-QA2 Gafchromic film is radiochromic film designed for dosimetric use in the energy range
20 - 200 kVp and within the recommended dose range 0.1 - 20 cGy. It has a strong energy
dependence in the kV range and the sensitivity of the film response increases for radiation
beams in the higher kV energy range46. For the same dose, Rampado et al.46 reported a
film response 72% lower for 28 kVp compared to 120 kVp. In the higher energy range (80 -
140 kVp), the maximum variation was less than 20%. The post-exposure film darkening is
most significant in the 24 hours after irradiation, although, small variations have been found
up to 4 days after exposure46. Similarly, a rigid scanning protocol was used when digitising
XR-QA2 film.
2.2.2 Calibration Procedure
EBT2 film calibration
Gafchromic EBT2 film has been shown to have little energy dependence in the megavoltage
energy range47 however, individual film calibrations were determined for the dose range 0 -
166 cGy for all energies used, namely, 6, 10 and 18 MV. Film calibration was carried out
on a Varian iX linear accelerator (Varian Medical Systems, Palo Alto, CA). The majority of
measurements were made for doses less than 50 cGy to ensure accuracy in the film calibration
at low doses. Gafchromic film (lot #:A10061001B, expiration date: October 2012) was cut
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into 4 x 4 cm2 pieces and marked to keep the orientation of the film consistent. A film piece
was placed in a 30 x 30 x 20 cm3 stack of Solid Water R© (Gammex RMI, Middleton, WI,
USA) at a depth of 5 cm. The centre of the film was aligned with the central axis of the beam
along the crosswires. The linear accelerator dose delivery is linear down to 3 Monitor Units
(MU), where 1MU is defined as 1 cGy to Dmax at a source to axis distance (SAD) of 100 cm,
in a 10x10 cm2 field. In order to ensure linearity of the beam at low doses, the solid water
was placed at an extended SSD. The ratio of dose delivered at isocentre in a water phantom
(10 x 10 cm2 field, 95 cm SSD) to that at the extended SSD in solid water (5 cm depth, 5 x
5 cm2, 200 cm SSD) was used to correct for the extended SSD setup. The correction factor,
Cext, accounts for the change in field size, SSD and any discrepancies between measurements
made in the water and solid water phantoms. Twelve pieces of film were irradiated with 0,
1, 2, 3, 4, 5, 10, 20, 50, 100, 150 and 200MU, respectively. This was repeated three times.
The dose (D) to the films was calculated from the delivered MU, with adjustments made
for the deviation of the machine output from calibration, Oc, which is the ratio between the
current machine output and that at calibration, the placement of the film at depth and the
extended SSD setup and is given by;
D = MU ×Oc × TMR× Cext
The Tissue Maximum Ratio (TMR) at a depth of 5 cm was 0.918, 0.956 and 0.990 for 6,
10 and 18 MV, respectively. The applied doses to calibrate EBT2 film in 6, 10 and 18 MV
beams are given in Table 2.1.
Table 2.1: The dose applied for calibration of EBT2 film ranged
0 - 166 cGy.
Applied Dose (cGy) for Film Calibration
Monitor Units (MU)
Energy 0 1 2 3 4 5 10 20 50 100 150 200
6 MV 0.0 0.8 1.5 2.3 3.0 3.8 7.5 15.1 37.7 75.4 113.1 150.8
10 MV 0.0 0.7 1.5 2.2 2.9 3.6 7.3 14.5 36.3 72.6 108.9 145.2
18 MV 0.0 0.8 1.7 2.5 3.3 4.1 8.3 16.6 41.4 82.8 124.2 165.6
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The film pieces were digitised one at a time using an Epson Expression 10000XL scanner
(Seiko Epson Corporation, Nagana, Japan) 24±1 h post irradiation. Films were placed at
the centre of the scanner bed, in a consistent landscape orientation, with the short edge of
the original film parallel to the scanning direction and the polyester substrate layer facing
the glass. The scanner was used in professional mode, with software selections transmission
and positive film and with all filters and colour corrections turned off. Images were acquired
in 48-bit colour, using a resolution of 72 dpi and saved in tagged image file format (TIFF).
The scanner was switched on 30 minutes prior to use and a preview, followed by three scans
to warm up the scanner before film digitisation commenced48,49. Additionally, a preview
scan was performed prior to each scan49. Gloves were worn at all times when handling the
film. The image files were imported into MATLAB R© (MATLAB R2011a, The MathWorks
Inc., Natick, MA) and the central 58 x 58 pixels (2 cm2) were extracted and separated into
red, blue and green channels. Care was taken to exclude any film area within 0.5 cm from
a cut film edge. A correction, recommended by the manufacturers, was applied to the red
channel data to smooth out possible inconsistencies in the thickness of the active layer50.
The pixel values were converted to optical density as follows:
OD = −log10(pixelvalue/65535)
For each film piece, the mean optical density of the corrected red channel data was plotted
against the applied dose to establish the calibration curve. The mean of the three calibration
curves was used for film analysis (Figure 2.2). For all EBT2 dosimetry measurements, the
above scanning protocol was used and unless stated otherwise, the central 0.5 x 0.5 cm2 (14 x
14 pixels) was extracted for film analysis. Figure 2.3 illustrates the weak energy dependence
of EBT2 film in the MV energy range.
The maximum uncertainty (2SD) of any point in the calibration curves was 2.0, 1.4 and
1.4% for 6X, 10X and 18X, respectively.
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(a) Dose range 0 - 150 cGy (b) Dose range 0 - 20 cGy
Figure 2.2: Red channel response for three sets of film irradiated to determine the 6 MV
calibration curve. The mean of the three measurements is also given (magenta).
XR-QA2 film calibration
XR-QA2 Gafchromic film was calibrated for measuring surface dose from Cone-beam CT and
CT image acquisition. Because of the strong energy dependence of the film in the kV energy
range, the beam qualities of the fore mentioned imaging modalities were determined prior to
calibration. The X-ray beam qualities of an On-Board Imager R© (OBI) v1.4 and cone-beam
CT capable Varian Linear Accelerator were measured for the standard CBCT protocols (100,
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Figure 2.3: Calibration curves for EBT2 Gafchromic film for beams of different megavoltage
energies.
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110 and 125 kVp). Clinically, an aluminium compensator (bowtie filter) is introduced into
the beam path to reduce the dose to the patient and improve image quality51,52. To assess
the greatest range of Half Value Layers (HVLs) the full bowtie filter was fitted. A Piranha
multimeter (RTI, Sweden) was used to evaluate the effects of the bowtie filter on HVLs on
the central axis and at longitudinal displacements up to 10 cm. The HVLs ranged 4.9 - 7.6
mm Al (mean HVL = 6.3 mm Al) over all assessed positions. The mean beam quality on
the central axis from the 3 protocols was 5.5 mm Al. The HVL increased off axis due to
beam hardening.
According to manufacturer’s specifications, the Siemens Somatom Sensation Open helical
scanner (Siemens Medical Solutions, Erlangen, Germany) HVL was 9.1 mm Al for a 120 kVp
imaging protocol. The dose delivered by the OBI X-ray source is unknown without the aid
of external dose meters and therefore, the OBI X-ray source is not suitable for calibrating
dosimeters. To overcome this, XR-QA2 Gafchromic film was calibrated on an XStrahl 300 X-
ray Therapy Unit (XStrahl Ltd., Surrey, UK) using a 150 kVp beam with beam quality HVL
= 6.0 mm Al, similar to those expected during CBCT acquisition. A 180 kVp beam with
beam quality HVL = 9.5 mm Al was used to calibrate the film for measurements on CT. The
150 and 180 kVp beams were calibrated in water under reference conditions, (30 cm SSD, 8
cm circle applicator for 150 kVp and 50 cm SSD, 10x10 cm2 applicator for 180 kVp) using
a NE2571 graphite cylindrical ionisation chamber (NE Technology Ltd, Reading, UK) with
a calibration traceable to a Secondary Standard Dosimetry Laboratory and in accordance
with the IAEA TRS 277 protocol53.
Gafchromic XR-QA2 film (lot #:A10071002A, Expiration Date: October 2012) was cut
into 4 x 4 cm2 pieces and marked with reference to the initial film orientation. The film was
placed on the surface of a 30 x 30 x 13 cm3 Solid Water R© phantom and the NE2571 ionisation
chamber was placed at a depth of 2 cm in the solid water to record the dose at depth (Figure
2.4). The film was calibrated under the beam reference conditions (30 cm SSD, 8 cm circle
applicator for 150 kVp and 50 cm SSD, 10x10 cm2 applicator for 180 kVp), henceforth
referred to as standard setup conditions. Ten pieces of film were irradiated with 0.0, 1.2,
2.2, 3.2, 5.2, 8.2, 10.3, 14.3, 17.3 and 20.4 cGy, respectively. This was repeated three times
9
for each energy. The delivered dose (D) to the film pieces was calculated from the recorded
ionisation chamber dose (Dion), with corrections made for measuring at depth, PDD, and in
a Solid Water R© phantom, Cp, and is given by:
D =
Dion × Cp
PDD
The Percentage Depth Dose (PPD) at 2 cm for the given beams is PDD150 kV p = 76.1%
and PDD180 kV p = 84.7%. The difference between measurements made in water and Solid
Water R© is 4.1% (Cp = 1.041) and 3.7% (Cp = 1.037) for 150 and 180 kVp, respectively.
Figure 2.4: XR-QA2 film calibration in a 180 kVp beam with standard setup conditions.
Films were digitised on an Epson Expression 10000XL scanner in reflection mode, with
software selection professional mode, photo and without any image corrections applied. Im-
ages were acquired in 48-bit colour, using a resolution of 72 dpi and saved in tagged image
file format (TIFF). The scanner warm up procedure, handling of film and image manipula-
tion were carried out as previously described for EBT2 film calibration. All XR-QA2 film
was digitised in this manner, with the central 0.5 x 0.5 cm2 (14 x 14 pixels) extracted for
analysis of dosimetry measurements, unless stated otherwise.
The response of the film in the red, green and blue channels is illustrated in Figure 2.5.
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The greatest sensitivity is observed in the red channel. The energy dependence of the film
is visible in the kV energy range (Figure 2.6).
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Figure 2.5: Red, green and blue channel response for one set of XR-QA2 film for beam
energy 150 kVp.
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Figure 2.6: Calibration curves for XR-QA2 Gafchromic film for beam energies 150 and
180 kVp.
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2.2.3 Uncertainty of Gafchromic Film
The reproducibility of EBT2 and XR-QA2 film with low dose delivery was assessed in MV
and kV beams, respectively. A 3 x 3 cm2 piece of EBT2 was placed in a 30 x 30 x 20 cm3 stack
of solid water (95 cm SSD) at a depth of 5 cm. A total of 20 pieces were exposed to 5 cGy in
a 6 MV beam. The mean dose to the central 0.5 x 0.5 cm2 was evaluated. The measurement
error increases rapidly for doses below 1 cGy in kilovoltage beams. Additionally, the error
was dependent on the energy of the beam46. For assessment in kilovoltage beams, a 3 x 3
cm2 piece of XR-QA2 film was positioned on the surface of a 30 x 30 x 13 cm3 stack of solid
water in standard setup conditions for 150 and 180 kVp. For each kV beam, 20 film pieces
were exposed to 2 cGy. The uncertainties (2 SD) in the measurements are given in Table
2.2.
Table 2.2: The reproducibility (95% CI) of Gafchromic film for low dose exposures.
Gafchromic Film Reproducibility (%)
Energy
Applied Dose
2 cGy 5 cGy
150 kVp 3.1 -
180 kVp 3.0 -
6 MV - 1.0
Despite the low applied dose, these findings are in agreement with previous reports41,42,46.
Richley et al.42 reported the uncertainty (2SD) of EBT2 to be 1.1 - 1.2% for applied doses
50 - 300 cGy with a 6 MV beam. In another study, the uncertainty (2SD) was reported as
2.4, 3.0 and 3.0% for applied doses with a 6 MV beam of 100, 200 and 300 cGy41. Rampado
et al.46 determined that for an applied dose of 2 cGy with a 140 kVp beam, the uncertainty
(2SD) of XR-QA2 was 6%.
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2.3 Metal Oxide Seminconductor Field Effect Transis-
tors (MOSFET)
2.3.1 Introduction
Metal oxide semiconductor field effect transistor (MOSFET) detectors are widely used for
clinical dosimetry29,30,54,55. They are highly sensitive, show little energy dependence in
the MV energy range56 and their small size and direct reading capability provides ease of
use. The operating principles of MOSFET detectors have been described previously57,58.
Essentially, a MOSFET consists of P-type silicon substrate, an oxide layer and a metal gate.
Ionising radiation creates charge in the silicon oxide layer resulting in a shift in the gate
voltage (threshold voltage). The shift allows charge conduction through the MOSFET and
is proportional to the dose deposited in the oxide layer.
Several authors have investigated the angular dependence of MOSFETs. Chuang et al.30
reported angular dependence of ±2.5% for 6 MV beams, while Ehringfeld et al.59 found
angular dependence of ±5.0% for 180 kVp and 250 kVp beams. This increased significantly,
> ±20%, for 100 kVp. Other limitations include large energy dependence in the kV range59
and a limited life time, usually around 20,000 mV.
In this work, measurements were made using high sensitivity TN-1002RD MOSFETs
(Thomson & Nielsen, Ottawa, Canada), with a high bias setting, in conjunction with the
AutoSense System.
2.3.2 Calibration Procedure
MV calibration
The energy dependence of MOSFETs in the megavoltage energy range 60Co - 15 MV is
reported to be 5%56. Despite the weak energy dependence, individual calibration factors
were determined for 6, 10 and 18 MV beams. MOSFETs were positioned with the black
bulb down (away from the beam), as per manufacturer’s recommendations, in a MOSFET
specific Perspex phantom created in the workshop at Auckland DHB (Figure 2.7). The
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phantom accommodates up to five MOSFETs. The Perspex phantom was placed on the
treatment couch at 100 cm SSD, with at least 10 cm Solid Water R© for backscatter, in a 10 x
10 cm2 field. 5 cm of Solid Water R© was placed on top of the Perspex phantom for build up.
Figure 2.7: The Perspex MOSFET phantom. The grooves accommodate the raised black
bulb and allow up to five MOSFETs to be calibrated simultaneously.
As recommended by the manufacturers, the MOSFETs were irradiated with sufficient
dose to cause a minimum 200 mV shift in the threshold voltage. The MOSFETs were read
out immediately. Five consecutive measurements were made ensuring at least five minutes
passed between each irradiation. This calibration process was carried out for all energies
as required or at approximate threshold voltages 0, 10,000 and 15,000 mV. The dose (D)
applied was calculated from the delivered MU with adjustments made for the deviation of
the machine output from calibration Oc and the placement of the MOSFETs at depth and
follows as:
D = MU ×Oc × TMR
The Tissue Maximum Ratio (TMR) at a depth of 5 cm is 0.918, 0.956 and 0.990 for 6, 10
and 18 MV, respectively.
The CF were determined from the mean of the five measurements:
CF =
mi
D
Where mi is the MOSFET reading in millivolts (mV).
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The mean CF for 6, 10 and 18 MV was 785.0 ± 11.3 mV/Gy, 784.8 ± 10.3 mV/Gy, 773.9
± 11.7 mV/Gy, respectively. The variation in CF across the MV energy range assessed was
1.4%. However, individual detector calibration factors were used.
kV calibration
MOSFET detectors were calibrated two at a time using the XStrahl 300 X-ray Therapy
Unit. Calibration factors (CF) were determined for 150 and 180 kVp beams. Two MOS-
FETs were placed on the surface of a solid water phantom (30 x 30 x 13 cm3) in standard
setup conditions (Figure 2.8), with the black bulb facing upwards (as recommended by the
manufacturers for kilovoltage energies), at a lateral displacement ±0.5 cm from the central
axis. A NE2571 graphite cylindrical ionisation chamber was placed at a depth of 2 cm to
measure the delivered dose. No interference in the ionisation chamber measurements was
expected due to the presence of the MOSFETs since they were laterally displaced. The
MOSFETs were irradiated with sufficient dose to result in a minimum signal of 200 mV,
as suggested by the manufacturers. Five measurements were recorded allowing at least five
minutes between each irradiation. The dose (D) delivered to the MOSFETs was calculated
from the ion chamber measurements, Dion, with corrections applied for measuring in solid
water and at depth and is given by;
D =
Dion × Cp
PDD
The Percentage Depth Dose (PPD) at 2 cm for the given beams was PDD150 kV p = 76.1%
and PDD180 kV p = 84.7%. The difference between measurements made in water and Solid
Water R© was 4.1% (Cp = 1.041) and 3.7% (Cp = 1.037) for 150 and 180 kVp, respectively.
The calibration factors were determined as previously described (equation 2.3.2). The
mean CF was 25.1 ± 0.7 mV/cGy and 23.7 ± 0.3 mV/cGy for 150 and 180 kVp, respectively.
A slight energy dependence was observed; the kV calibration factors differed by 5.7%. The
difference between detector calibration factors for the same energy was up to 14.4%. This
agrees with the findings of Enringfeld et al.59, who observed variations in detector calibration
factors greater than 10% for energies below 180 kVp. This highlights the importance of using
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individual calibration factors.
2.3.3 Uncertainty of MOSFETs
Several authors have reported on the uncertainty of metal oxide semiconductor field effect
transistors for doses typical in a treatment fraction. For a dose delivery of approximately
1 Gy in a 6 MV beam, Gopiraj et al.56 determined the reproducibility of low and high
sensitivity MOSFETs to be 1.4% and 2.0% (1SD), respectively. Bulinski et al.60 evaluated
the reproducibility of MOSFETs in a 6 MV beam for a range of doses (17 - 100 cGy). The
standard deviation was 3.7% for the lowest applied dose and 0.9% for the highest. Ehringfeld
et al.59 investigated the reproducibility of multiple MOSFET detectors (standard sensitivity,
standard bias sensitivity) with energies 80 - 250 kVp and applied doses 0.2 - 2.5 Gy. The
largest deviation, ±7.4%, was observed for applied doses equal to or less than 1 Gy. The
maximum deviation for doses between 1.5 and 2 Gy was ±2.5% and for applied doses of
2.5 Gy, ±1%. Cheung et al.61 reported the repeatability of a MOSFET for 50 consecutive
irradiations of applied dose 100 cGy with a 250 kVp beam to be 2.6% (2SD of mean).
Figure 2.8: MOSFET detector calibration in a 150 kVp beam with standard setup conditions.
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However, reports on the reproducibility of MOSFETs for doses less than 20 cGy, which are
common in the periphery of treatment fields and in imaging fields, are scarce in the literature.
The reproducibility of high sensitivity TN-1002RD MOSFETs with low dose delivery
was assessed in MV and kV beams. Four MOSFETs were placed in the MOSFET Perspex
phantom, positioned centrally in a 10 x 10 cm2 field (100 cm SSD, 2 cm depth), on a 30 x 30
x 10 cm3 block of solid water. A total of 12 readings were recorded for an exposure of 2 and
5 cGy in a 6 MV beam. For evaluation in kilovoltage beams, two MOSFETs were positioned
on the surface of a 30 x 30 x 13 cm3 stack of solid water in standard setup conditions for
150 and 180 kVp. A total of 20 measurements were recorded for an exposure of 2 cGy.
The uncertainties (2 SD) are given in Table 2.3. The reproducibility of MOSFET detectors
for measuring low dose is poor for all energies investigated, with measurement uncertainties
measurement of up to 54%. Despite this, the nominal dose inaccuracy is approximately
1cGy.
Table 2.3: The percentage uncertainty (95% CI) in high sensitivity MOSFETs for low dose
exposures.
MOSFET Reproducibility
Energy
Applied Dose
2 cGy 5 cGy
150 kVp 26.6 -
180 kVp 50.4 -
6 MV 53.6 18.1
2.4 Comparison of Dosimeters
The dose response of MOSFETs and Gafchromic Film (hereafter referred to as the dosime-
ters) was investigated to determine the suitability of using these dosimeters in primary
kilovoltage (kV) and peripheral region of megavoltage (MV) beams. Dose in the peripheral
regions of the MV treatment field is complex; with dose contributions from scatter within
the patient (internal scatter), leakage from the head of the treatment machine (head leakage)
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and collimator scatter. Internal scatter is the major contributor of dose in the near periph-
ery of the treatment field, having spectra peaks near 500 keV, while head leakage dominates
further a field62. The out-of-field dose is largely dependent on beam energy, field size and
distance from the field edge62–64. The photon contribution decreases exponentially with dis-
tance from the field and the neutron contribution, which is significant for beam energies ≥
15 MV, is independent of distance from the field but decreases with depth in tissue65. All
these factors influence the choice of appropriate dosimeter to quantify peripheral dose.
2.4.1 Megavoltage Beam
MOSFET and Gafchromic film measurements were compared to those made with an IBA
CC13 ionisation chamber (IBA Dosimetry, Beijing, China) which, due to low angular de-
pendence and weak energy dependence across a broad spectrum (100 kVp to 50 MV), is a
suitable reference dosimeter for out of field measurements. The dose response of the dosime-
ters under investigation was performed using a Varian iX 6 MV beam with the response to
higher energies assumed to be similar since the energy dependence of EBT2 and MOSFETs
is small in the MV energy range47,56.
The response of the CC13 ionisation chamber and UNIDOS electrometer system (PTW,
Freiburg, Germany) was established for the delivery of a range of doses (1.9 - 186.2 cGy). A
Scanditronix-Wellho¨fer water phantom system (Scanditronix-Wellho¨fer, Uppsala, Sweden)
was set up with the CC13 ionisation chamber positioned at a depth of 5 cm in a 10x10 cm2
field, at 95 cm SSD. The mean of two readings were recorded for each dose delivery.
Peripheral dose measurements were made at increasing distances from the edge of a 10x10
cm2 irradiated field using the CC13 ionisation chamber with the effective point positioned on
the surface of the water, 1 cm from the edge of the field. Two peripheral dose measurements
were made for the dose delivery on the central axis of 101.4 cGy to dmax. Measurements
were repeated at 2, 3, 4, 5, 6, 8 and 10 cm from the field edge and again at 3, 4, 5, 6, 8 and
10 cm for the delivery on the central axis of 202.9 cGy to dmax.
3 x 3 cm2 pieces of EBT2 film were positioned on the surface of a 30 x 30 x 20 cm3 stack
of Solid Water R© (95 cm SSD), at distances 1, 2, 3, 4, 5, 6, 8 and 10 cm from the edge of
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a 10 x 10 cm2 field. The sequence of film irradiation was such that the film pieces did not
overlap and interfere with the recorded dose. Individual sets of film pieces were exposed
to peripheral dose from dose deliveries on the cental axis to dmax of 101.6 and 203.3 cGy,
respectively. These measurements were repeated three times and the film was digitised 24
hours later.
Eight MOSFETs were used to carry out the same measurement described above, with
doses prescribed to dmax on the cental axis of 101.5 and 203.1 cGy, respectively. The MOS-
FETs were read out after each irradiation.
The mean (95% CI) of the measurements for each dosimeter was recorded (Table 2.4).
The uncertainty in the CC13 ionisation chamber measurements was 1% as specified by the
manufacturers. The measured values were normalised to the CC13 ionisation chamber water
surface dose measurements at the respective distances. These values are compared in Figure
2.9.
Table 2.4: The peripheral dose measured by EBT2 and MOSFETs dosime-
ters at distances (D) from the edge of a 10 x 10 cm2 field were compared to
CC13 ionisation chamber measurements (Ion). Dosimeter measurements
were made on the surface of a stack of solid water. Comparisons were made
for applied doses of 101 and 203 cGy. The uncertainty in the ionisation
measurements is 1%. All values are given in cGy.
Peripheral Dose Dosimeter Comparison
Applied Dose = 203 cGy Applied Dose = 101 cGy
D (cm) Ion MOSFET EBT2 Ion MOSFET EBT2
1 - 14.23±2.08 15.14±0.61 7.43 6.59±1.32 8.04±0.87
2 - 12.20±2.06 12.13±0.45 5.67 6.04±0.44 5.69±0.42
3 9.33 8.60±0.38 10.30±1.49 4.58 4.28±0.60 5.63±0.95
4 7.83 7.43±0.62 9.09±1.17 3.91 3.76±0.44 4.10±0.15
5 6.62 6.59±0.81 7.64±1.08 3.36 3.40±0.52 3.79±0.25
6 5.80 3.42±0.73 6.94±0.98 2.82 1.29±1.59 2.94±0.45
8 4.45 2.12±1.08 4.47±0.18 2.15 0.27±0.43 2.04±1.00
10 3.64 2.53±2.29 4.31±0.21 1.74 1.45±1.01 2.44±0.51
Overall, EBT2 tended to overestimate the dose and MOSFETs tended to underestimate
the dose. For measurements up to 5 cm from the field edge, MOSFET measurements were
in better agreement with the CC13 ion chamber measurements (10% variation) compared to
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those made with film (25% variation). However, at greater distances, where the scatter con-
tribution is reduced, the accuracy of the MOSFETs decreased. This finding is in agreement
with other studies66,67. The maximum variation from the CC13 ion chamber measurements
was 2.4 and 1.3 cGy for MOSFETs and EBT2, respectively.
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Figure 2.9: The comparison of EBT2 Gafchromic film and MOSFETs dosimeters for mea-
surements in the periphery of a 6 MV beam. Doses were measured for a delivery of 101 and
203 cGy to dmax on the central axis of a 10x10 cm
2 field and normalised to those measured
with a CC13 ionisation chamber.
2.4.2 Kilovoltage Beam
In order to accurately measure dose within CBCT and CT fields, the suitability of MOSFETs
and XR-QA2 Gafchromic film for measuring dose within kV beams was determined. These
imaging techniques have beam qualities equivalent to 150 and 180 kVp, respectively. The
energy dependence of MOSFETs in the kilovoltage energy range is well known59,67, exceeding
10% over the energy range 80 - 250 kVp. The energy dependence of XR-QA2 is approximately
10% over the range68. Consequently, the dose response of the dosimeters was compared with
a NE2571 graphite cylindrical chamber for measurements made within both the 150 and 180
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kVp beams. All measurements were performed using the XStrahl 300 X-ray Therapy Unit.
Two MOSFETs were positioned centrally on a stack of solid water, at least 10 cm high
to ensure sufficient backscatter. The MOSFETs were displaced 0.5 cm lateral of the central
axis to avoid interfering with the NE2571 ionisation chamber, which was placed at a depth
of 2 cm on the central axis. Measurements were made under calibration conditions, i.e.,
30 cm SSD, with an 8 cm circle applicator fitted for the 150 kVp beam and 50 cm SSD,
with a 10 x 10 cm2 applicator fitted for the 180 kVp beam. Measurements were made for a
delivery of 1.1, 3.2, 5.2 and 10.3 cGy. The measurements were repeated three times and the
MOSFETs were read out between each measurement, allowing at least 5 minutes between
each irradiation.
Under the same conditions, three measurements were performed using XR-QA2 Gafchromic
Film. The film was cut into 3 x 3 cm2 pieces and fixed centrally using tape. The film was
digitised 46 hours after irradiation.
The mean (95% CI) of the measurements is given in Table 2.5. The numerical values
were normalised to the applied dose and the ratios are represented graphically in Figure
2.10.
Table 2.5: A comparison of the dose response of MOSFETs and XR-QA2 in kilo-
voltage beams of quality 150 and 180 kVp for the applied doses of 1.1, 3.2, 5.2 and
10.3 cGy as measured with the NE2571 graphite cylindrical chamber.
Dosimetric Response in Kilovoltage Beams
150 kVp 180 kVp
Applied Dose (cGy) MOSFET XR-QA2 MOSFET XR-QA2
1.1 1.12 ± 0.20 1.43 ± 0.02 0.81 ± 0.19 1.37 ± 0.02
3.2 3.26 ± 0.12 3.14 ± 0.02 2.90 ± 0.23 3.08 ± 0.02
5.2 5.47 ± 0.10 4.97 ± 0.01 4.97 ± 0.08 4.93 ± 0.02
10.3 11.25 ± 0.39 10.27 ± 0.01 10.33 ± 0.34 10.23 ± 0.07
XR-QA2 measures within 5% of the NE2571 ionisation chamber measurements for doses
above 3 cGy but overestimates the dose by approximately 25% for a dose delivery of 1.1
cGy. This dose is approaching the limit of the recommended dose range 0.1 - 20 cGy. XR-
QA2 film has excellent precision across the delivered dose range. MOSFET measurements
are within 10% of the ionisation measurements for doses above 3 cGy. For a dose delivery
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of 1.1 cGy, MOSFETs underestimate the dose on average by approximately 25% and 2%
for measurements within the 150 and 180 kVp beam, respectively. The associated error is
approximately 20%. Overall, MOSFETs and XR-QA2 are in good agreement (± 10%) with
the NE2571 ionisation chamber for doses above 3 cGy.
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Figure 2.10: The comparison of XR-QA2 Gafchromic film and MOSFETs dosimeters for
measurements made with 150 and 180 kVp orthovoltage beams. The measured doses were
normalised to the applied doses, measured with a NE2571 graphite cylindrical ionisation
chamber.
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2.5 Concluding Remarks
In this chapter the suitability of TN-1002RD MOSFETs and Gafchromic film was investi-
gated for measuring dose in the kV and MV range. MOSFETs are accurate dosimeters for
measuring peripheral dose close to the irradiated field. At distances > 5 cm, the inaccuracy
increases to 25%. The accuracy in MOSFET measurements within kV beams was found
to be 10%. XR-QA2 is accurate to within 5% for measurements made within 150 and 180
kVp beams and exposures above 3 cGy. EBT2 Gafchromic film overestimates the dose by
approximately 20% in the peripheral regions of MV beams. The reproducibility of MOS-
FETs for low dose deliveries was 26.6 and 50.4% in 150 and 180 kVp beams, respectively.
In megavoltage beams, the reproducibility was 18.1%. Gafchromic film has good precision
at low doses. The reproducibility of EBT2 for MV energy was 1.0%. For 150 and 180 kVp,
the uncertainty of XR-QA2 film was 3.1 and 3.0%, respectively.
In the next chapter the relevant risk models are introduced to evaluate the risks associated
with the doses measured using the above dosimeters.
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Chapter 3
Risk Analysis
3.1 Introduction
Radiation induced second malignancies following radiotherapy are of concern, especially
for younger patients who have a long life expectancy. Modern treatment techniques rely
on image guidance to ensure the accurate targeting of tumour volumes and to minimise
normal tissue toxicity69–71. Additionally, on-treatment imaging is used to observe inter-
and intrafraction organ and tumour motion and may be performed as often as twice per
fraction72,73. Although the dose from Cone-beam CT (CBCT) imaging is a fraction of that
from planning CT, the dose is not insignificant when daily imaging is considered2. In this
work, the risk of radiation-related cancer, due to radiotherapy and the necessary imaging,
was assessed using an array of models; namely, the competition model74 and the Biological
Effects of Ionizing Radiation (BEIR) excess relative risk (ERR) and excess absolute risk
(EAR) models, given in the BEIR VII phase II report75.
3.2 Competition Model
The competition model takes into account the probability of inducing DNA mutations and
the probability of the cells surviving irradiation. It is based on the linear quadratic equation
and accounts for fractionated radiotherapy and can be expressed as:
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Effect =
(
α1D +
β1D
2
n
)
× exp
[
−
(
α2D +
β2D
2
n
)]
(3.1)
where D is the total dose given in n fractions, α1 and β1 are radiation induced mutation
parameters and α2 and β2 are cell survival parameters. The α/β ratios are assumed to be the
same for the first (induction of DNA mutation) and second (cell survival) terms. α1 values are
rare in the literature, consequently approximations were made for this evaluation as suggested
by Das¸u et al.74. The quadratic terms in Equation 3.1 become insignificant at very low doses,
resulting in an approximate linear relationship between dose and effect. Thus, the slope of
the curve, α1, is assumed to be equal to the risk coefficients found from epidemiological
studies of populations irradiated with low doses74. These linear risk coefficients are obtained
from ICRP76.
The non-homogeneity of the dose distribution across the volume of concern is accounted
for by calculating the risk in every dose interval of the dose-volume histogram, which is then
summed to establish the total effect and follows as:
Total effect =
∑
i
(
vi × Effect(Di)
)
∑
i
vi
(3.2)
Where vi is the volume of tissue receiving dose Di . In this work, the organ at risk volume
was subdivided in the treatment planning system (TPS) such that the subvolumes centred
around a measurement point. The dose measured using dosimeters on the surface of each
subvolume was assumed to be the dose delivered to the whole subvolume. The competition
model was used to determine the secondary cancer risk associated with dose in the periphery
of the treatment fields and due to imaging.
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3.3 Excess Relative Risk and Excess Absolute Risk
Models
For comparison, additional models were used. The BEIR VII ERR and EAR models assume a
linear relationship between dose and risk and are specific for low levels of ionising radiation
(0 - 100 mGy). The excess absolute risk is the difference in incidence rates between the
exposed and unexposed population and is the number of excess cases per 10,000 people
per year. The relative risk (RR) is the ratio between incidence rates of the exposed and
unexposed population and the excess relative risk is specified as, ERR = RR - 1. ERR and
EAR are given by the same formula, however, the parameters are specific for each model:
ERR and EAR = β D exp[γe∗]
( α
60
)η
(3.3)
where D is the dose (Sv); β is a sex specific risk coefficient which corresponds to the ERR/Sv
and EAR/Sv at exposed age 30 and attained age 60 for ERR and EAR, respectively; α is
the attained age (years); η is the exponent of attained age; γ is the per-decade increase in
age at exposure over the range 0-30 years;
e∗ =

(e− 30)/10, if e < 30
0, if e ≥ 30
and e is the age of treatment (exposure);
The EAR and ERR risk models do not account for fractionation in treatment regimes
and therefore, the benefits of the optimum therapeutic ratio between tumour control and
late effects are unaccounted for. Despite this, these models were used to calculate the risk
of radiation related cancer from dose exposures ≤ 1 Gy (e.g., from CT and CBCT scans)
and the results were compared against the risks determined using the competition model.
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3.4 Concluding remarks
In the absence of a single generally accepted model, several candidate models were used to
calculate the approximate risk of radiation induced cancer. However, these models are not
without limitations. The competition model, which factors in the probability of inducing
DNA mutations and the probability of the cells surviving irradiation and accounts for frac-
tionation in the dose delivery, is limited by the availability of specific model parameters, i.e.,
α1. Furthermore, the competition model is designed to be used with dose volume histogram
data from the treatment planning system to sum the effects of the dose per volume across
the organ at risk, whereas, in this work, measured organ at risk doses to specified volumes
were used. Fractionation is unaccounted for when using the EAR and ERR models, and
consequently, the reduction in late site effects due to the improved therapeutic ratio is not
considered. Nevertheless, for doses below 1 Gy, the ERR and EAR were calculated and
compared with the competition model results.
The risk of radiation induced cancer was assessed for healthy tissue exposed to dose from
CT, CBCT and concomitant dose from radiotherapy delivery.
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Chapter 4
Case Study 1: Seminoma
4.1 Introduction
Testicular cancer is rare, having a global incidence of 0.8% of male cancers, with a slightly
increased incidence in westernised countries (New Zealand 1.2%)77. It is the most common
cancer in males of age 19-39 years in New Zealand77 but remains one on the most curable
cancers if treated in the early stages (5-year relapse-free rate of 95-97%)78,79. Almost all
testicular cancer originate in the germ cells and are classified as either seminoma or non-
seminoma cancers.
Testicular seminoma has a predictable disease progression, metastasising to the paraaortic
lymph nodes80. For patients with a history of un-descended testes and/or abnormal nodal
drainage, there is an increased risk of disease spread to the pelvic and ipsilateral common iliac
lymph nodes80. Stage I seminoma is treated by orchidectomy followed by one of the following:
surveillance, chemotherapy or radiotherapy to the paraaortic lymph nodes, including pelvic
and iliac lymph nodes where appropriate. Lead shielding is routinely used to protect the
remaining testis from radiation for patients undergoing radiotherapy inclusive of the pelvic
and ipsilateral common iliac lymph nodes. Even though the testis is well removed from the
paraaortic irradiation fields, scattered dose in the order of 1-6% of the prescribed dose has
been measured19,20. The testicular dose was reduced to 0.4-3% when some form of gonadal
shielding was fitted and consequently, the use of shielding is encouraged regardless of the
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treatment field19,20.
Since testicular seminoma occurs in a relatively young population, who after treatment
have a long life expectancy, the risk of radiation induced cancer to the contralateral testis
and the late side effect of infertility are of concern. A retrospective study assessing patients
at least three years after treatment for testicular cancer found a 30% decrease in fertil-
ity. Treatment therapies included orchiectomy followed by either surveillance, radiotherapy
and/or chemotherapy and radiotherapy was shown to have the greatest detrimental effect
on fertility18.
In this work the accumulative dose a patient receives while undergoing radiation treat-
ment for testicular seminoma was measured to assess the risk of secondary cancer and late
side effects. Dose contributions from CT, CBCT and treatment scatter were considered.
Both paraaortic lymph node and extended field treatments were assessed with and without
the lead shielding fitted.
4.2 Materials and Methods
A Varian iX linear accelerator (Varian Medical Systems, Palo Alto, CA) was used to deliver
treatment to an anthropomorphic phantom. Radiation doses were measured with Gafchromic
film and TN-1002RD MOSFET dosimeters and compared to the predicted dose of TPS. The
treatment plans were created in Pinnacle3 and computed using the collapsed cone convolution
algorithm and a 4 mm dose grid. The potential risk of second testicular cancer due to
radiotherapy treatment for seminoma was assessed using risk models (Chapter 3).
4.2.1 Treatment Planning Techniques
A Rando Phantom (Alderson Research Laboratories, Long Island City, New York) fitted with
a wax scrotum (density = 0.9g/cm3) moulded in the department workshop was positioned on
the CT couch. Three surface measurement points were identified and marked with tape; one
on the anterior, one on the posterior scrotal surface and one on the abdomen 5 cm superior
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to the superior edge of the wax mould. These can be seen in Figure 4.1. Additionally, this
tape prevented wax residue on the Gafchromic film. Lead gonadal clam-like shielding is
used at treatment to protect the remaining testis, however, this results in image artefacts
if fitted at CT imaging. To accommodate this, a replicate constructed from PVC is used.
Both the pseudo and lead clam gonadal shielding were crafted in the department workshop.
The phantom was scanned on a Siemens Somatom Sensation Open helical scanner (Siemens
Medical Solutions, Erlangen, Germany) following departmental protocol for pelvis CT scans
(120kV, 148 mA, 3 mm slice thickness). The scan extended from the T7/T8 joint to mid
femur. The data set was exported for planning.
Figure 4.1: Rando positioned on the treatment couch with the posterior lead shielding
fitted. MOSFETs are positioned at the abdominal and anterior scrotal measurement points
demarcated by the green tape.
Two treatment plans consisting of an anterior/posterior parallel opposed beams were
created using 18MV photons in Pinnacle3 (Philips Medical Systems, Milpitas CA). The
paraaortic (PA) plan consisted of a rectangular field 20 cm long and 8 cm wide to include
the paraaortic lymph nodes with a prescribed dose of 20 Gy in 10 fractions. The kidneys
were shielded by multileaf collimators (MLCs). This treatment was prescribed to 100% of
the dose at the isocentre, which corresponds to the zero slice in the data set. The posterior
beam (Gantry = 180◦) was a mirror of the anterior beam (Gantry = 0◦). The anterior
beam digitally reconstructed radiograph, DRR, (Figure 4.2) shows the treatment field and
kidney shielding. The second treatment plan, commonly referred to as a dogleg (DL), was
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an extension of the PA to include the ipsilateral pelvic and common iliac lymph nodes with
a prescribed dose of 30 Gy in 18 fractions. The prescription isocentre was positioned more
inferiorly than in the paraaortic treatment plan and MLCs were used to shield the kidneys
and the remaining testis (Figure 4.3). Again, the posterior beam was a mirror of the anterior
treatment beam. The isodose distributions from the respective plans are shown in Figure
4.2, 4.3.
(a) A digitally reconstructed radiograph of
the anterior treatment beam.
(b) A coronal view of the isodose distribu-
tion at the CT reference point.
Figure 4.2: The paraaortic treatment plan. (a) The centre of the beam is aligned with the
isocentre (red wireframe sphere). (b) The pink and red isodose lines represent the 95% and
100% dose coverage, respectively.
(a) A digitally reconstructed radiograph of
anterior treatment beam.
(b) A coronal view of the isodose distribu-
tion at the CT reference point.
Figure 4.3: The Dogleg treatment plan. (a) The MLCs shielding the kidneys and testis can
be seen in the DRR. (b) The turquoise, red and pink isodose lines represent the 102%, 100%
and 95% dose coverage, respectively.
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4.2.2 Measurements
CT
The Rando anthropomorphic phantom was positioned on the CT scanner bed and aligned
with the lasers. A MOSFET was placed at the centre of the anterior and posterior scrotal
and abdominal positions. The pseudo lead clam shielding was positioned to enclose the
scrotum. Following departmental protocol, a topogram (scout scan) was carried out prior
to a CT scan. The MOSFETs were read out within five minutes after each CT scan. The
measurements were repeated three times with and three times without the clam shielding
fitted. XR-QA2 Gafchromic film was positioned at the same locations and secured with
tape, ensuring no more than 0.5 cm in from the film edge was covered. 1.5 x 3 cm2 film
strips were placed at the anterior and posterior scrotal positions and a 3 x 3 cm2 piece of
film was placed at the abdominal position. Using the same scanning technique, three CT
scans were carried out with gonadal shielding and three without. An unexposed film piece
was used for each scan. In keeping with calibration, the film was digitised 46 hours post
irradiation and analysed as previously described.
CBCT
Rando was positioned on the treatment couch with the lead shielding in place and aligned
with the lasers to the CT reference point. The half bow tie was fitted and a pelvis CBCT
image, using the standard imaging protocol (125 kVp, 706 mA s, 360◦), was taken for pre-
treatment image matching. The CBCT field was 16 cm wide, inclusive of the abdominal
measurement point, however, the scrotum lay out of the imaging field. Three CBCT images
were performed with XR-QA2 film in place and three with MOSFET dosimeters. These
were repeated without the shielding fitted.
Treatment
EBT2 Gafchromic film was cut to size, 3 x 1.5 cm2 for the scrotal measurement points and 3
x 3 cm2 for the abdominal point and secured in place using tape. The orientation of the film
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was kept consistent and care was taken to ensure that no more than 0.5 cm in from the film
edge was covered with tape. Rando was set up on the treatment couch, with the gonadal
shielding fitted, using localisation lasers to match the position at CT. One fraction of the
paraaortic treatment was delivered. A total of three measurements with shielding and three
without shielding were performed. These measurements were repeated with MOSFETs.
Measurements were carried out in the same manner for the dogleg treatment plan, using
both MOSFET and film dosimeters.
(a) Full lead shielding fitted. (b) Gafchromic film placement.
Figure 4.4: (a) Rando set up on the treatment couch with EBT2 film positioned at the
measurement points. The treatment gantry angle is not shown.(b) Half the clam shielding is
removed showing the placement of the film dosimeter. (The posterior scrotal measurement
point is not seen.)
4.2.3 Pinnacle3 Dose
The PVC shielding was contoured in the TPS and the density was overridden to that of
lead (11.3 g/cm3). Points of interest (POIs) were created at the three respective measure-
ment points, directly below the external contour for comparison with doses measured with
Gafchromic film. MOSFET dosimeters have an inherent build up of 1 mm due to the epoxy
bulb. In order to compensate for this, additional POIs were created at a depth of 1 mm be-
low the first set of points. The dose was recorded at each POI and at five surrounding points
located 2 mm inferior, superior, posterior and lateral (two points) of the POI, respectively.
The dose was not recorded anteriorly as this was in air. The mean of the six point doses
was compared to the measured doses made with shielding fitted.
33
4.2.4 Risk Analysis
The competition, BEIR VII ERR and EAR models were used to assess the risk of radia-
tion induced cancer in the remaining testis as a result of the accumulative dose received
throughout the treatment process. These models have been previously described (Chapter
3). The mean of the anterior and posterior testicular dose was employed in all models for
risk assessment.
An α/β ratio of 12-13 Gy81,82 for early responding normal testis tissue was used for the
competition model. The nominal risk co-efficient, α1 = 2x10
-3 Gy-1 and α2 = 0.25 Gy
-1 are
assumed, resulting in β1 and β2 values of 1.67x10
-4 and 2.08x10-2, respectively74,76.
For the BEIR VII model, no specific risk model parameters are given for estimating
cancer incidence from dose to the testis. As such, the risk model parameters for all solid
cancers, which excludes thyroid and nonmelanoma skin cancers, were used. For the given
ERR parameters, β = 0.33 (0.24, 0.47 95% CI), γ = -0.30 and η = -1.4, and dose, D, the
testicular cancer risk is given by;
ERR = D 0.33 exp[−0.3e∗]
( α
60
)−1.4
The EAR model, with parameters β = 22 (15, 30 95% CI), γ = -0.41 and η = 2.8, results
in an estimate of the additional cancer incidence per 10,000 people per year and is given as
follows:
EAR = D 22 exp[−0.41e∗]
( α
60
)2.8
where,
e∗ =

(e− 30)/10, if e < 30
0, if e ≥ 30
α is the attained age, and
e is the age at treatment (exposure).
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These models were evaluated for exposed ages, e = 25 and 35 y and attained ages 20 years
later; α = 45 and 55 y.
The risk of radiation induced cancer due to CBCT was assessed for two common imaging
schemes: daily (n=18) and imaging the first three days followed by weekly CBCT (n=6).
The CT associated risk was calculated assuming only one CT was performed.
4.3 Results
4.3.1 CT & CBCT Imaging
The mean (95% CI) of the measurements recorded while acquiring images is given in Table
4.1. For CBCT imaging using XR-QA2, a dose reduction to the testis of more than 50%
is seen when the lead shielding is fitted. In contrast, the anterior and posterior MOSFET
measurements were 0.01 and 0.13 cGy with shielding and 0.03 and 0.09 cGy without, showing
little variation between those with and without shielding present and falling within the 95%
CI. The dosimeters were positioned at least 5 cm from the inferior edge of the imaging field,
resulting in a low particle flux to this point. Furthermore, the signal is attenuated by the
lead shielding and the epoxy bulb, for MOSFETs. The dosimeter results from CT acquisition
are in good agreement. With the pseudo shielding fitted, the dose to the testis is reduced
by approximately 50%.
4.3.2 Treatment Delivery
The mean (95% CI) of the dose measurements acquired for DL and PA treatment deliveries
are given in Table 4.2. In general, less dose was recorded for the paraaortic treatment. This
was expected as the DL fields were closer to the measurement points. MOSFET and EBT2
film measurements were in good agreement at the abdomen for all treatment scenarios.
At the anterior scrotum, a dose reduction of approximately 1/4 was seen with the gonadal
shielding fitted when measuring with EBT2 film. Contrary to this, little change was recorded
at the posterior scrotal position when the shielding was fitted. The MOSFET measurements
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Table 4.1: The results displayed are for a single scan of each imaging
technique. Measurements were made with and without gonadal shield-
ing present.
Imaging Dose (cGy)
Dosimeter Technique Shielding
Regions of Interest
Abdomen ANT POST
MOSFET
CBCT
Y 2.19 ± 0.76 0.01 ± 0.03 0.13 ± 0.26
N 3.09 ± 0.23 0.03 ± 0.05 0.09 ± 0.18
CT
Y 2.38 ± 0.27 1.36 ± 0.24 1.17 ± 0.15
N 2.60 ± 0.42 2.40 ± 0.67 2.71 ± 0.25
XR-QA2
CBCT
Y 3.25 ± 0.03 0.19 ± 0.01 0.02 ± 0.01
N1 3.26 ± 0.02 0.49 ± 0.01 0.46 ± < 0.01
CT
Y 2.63 ± 0.12 1.70 ± 0.04 1.26 ± 0.05
N 2.56 ± 0.18 2.28 ± 0.17 2.35 ± 0.05
1 The mean of two measurement sets. The third set was discarded due to visible
anomalies.
at the testicle are a fraction of the film results (< 1/3). This is due to the low particle flux
at these positions, which is attenuated further by the epoxy bulb and the lead shielding.
The mean (95% CI) of the point dose measurements predicted in the treatment planning
system are given in Table 4.3. The TPS predicted doses to the testis are approximately 1/3
of those measured with Gafchromic film for DL treatment fields. For this plan delivery, the
MOSFET results were in better agreement with the TPS, however, they in themselves had
large uncertainties. Overall, there was little agreement with the measured results.
Table 4.2: Dose measurements were recorded with and without lead
shielding fitted for paraaortic and dogleg treatment techniques.
Seminoma Treatment Dose (Gy)
Dosimeter Technique Shielding
Regions of Interest
Abdomen ANT POST
MOSFET
Dogleg
Y 1.34 ± 0.28 0.18 ± 0.19 0.08 ± 0.06
N 1.23 ± 0.40 0.26 ± 0.31 0.06 ± 0.07
PA
Y 0.49 ± 0.11 0.08 ± 0.11 0.00 ± 0.00
N 0.50 ± 0.18 0.00 ± 0.00 0.03 ± 0.12
EBT2
Dogleg
Y 1.72 ± 0.06 0.63 ± 0.02 0.59 ± 0.10
N 1.77 ± 0.02 0.83 ± 0.17 0.53 ± 0.28
PA
Y 0.70 ± 0.07 0.32 ± 0.04 0.27 ± 0.06
N 0.68 ± 0.11 0.43 ± 0.02 0.19 ± 0.02
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Table 4.3: Seminoma point doses in the TPS.
TPS Point Dose (Gy)
Point Depth Abdomen Anterior Posterior
Dogleg
Surface 1.53 ± 0.12 0.19 ± 0.01 0.16 ± 0.01
1 mm 1.74 ± 0.08 0.19 ± 0.01 0.16 ± 0.01
PA
Surface 0.14 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
1 mm 0.15 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
4.3.3 Risk Analysis
The risk of radiation induced testicular cancer was assessed for concomitant doses received
while undergoing radiotherapy for testicular seminoma (Table 4.4). The mean of the anterior
and posterior scrotal doses over the course of treatment was evaluated. As a conservative
approach, the maximum dose was used to assess risk (i.e., Gafchromic film results). ERR
and EAR models were used to calculate the risk of cancer 20 years after the initial treatment,
assuming first treatment at either 25 or 35 years of age. The risk of radiation induced cancer
decreases with increasing age of first treatment. The accumulative risk, which combines the
risk associated with treatment and imaging, was calculated for the ERR and EAR models,
assuming treatment at 25 years of age. In summary, the EAR model estimates an additional
7.4 and 8.3 cancers per 10,000 people per year treated for seminoma with dogleg fields, with
and without shielding, respectively. This estimate was 3.6 and 3.9 for paraaortic fields. The
risk of radiotherapy treatment for seminoma inducing cancer in the remaining testis is 0.4%
and 0.2% for dogleg and paraaortic treatments irrespective of gonadal shielding.
37
Table 4.4: Risk estimates of radiation induced testicle cancer based
on the ERR, EAR and competition risk models. EAR and ERR were
calculated at 20 years post treatment for age at treatment of 25 or
35 years (e = 25, 35y and α = 45, 55y). The results are given as
25y / 35y. The accumulative risk from CT, daily CBCT and treat-
ment was considered at treatment age of 25y.
Testicular Cancer Risk Estimates
Risk Model Radiation Source Shielding No Shielding
Competition
Model
Dogleg 0.10% 0.12%
Paraaortic 0.06% 0.06%
CBCT n = 6 0.001% 0.006%
n = 18 0.004% 0.017%
CT 0.003% 0.005%
ERR
Dogleg 0.35% / 0.17% 0.39% / 0.19%
Paraaortic 0.17% / 0.08% 0.18% / 0.09%
CBCT n = 6 0.004% / 0.002% 0.016% / 0.008%
n = 18 0.011% / 0.005% 0.049% / 0.023%
CT 0.008% / 0.004% 0.013% / 0.006%
EAR
Dogleg 7.36 / 6.98 8.21 / 7.78
Paraaortic 3.56 / 3.37 3.74 / 3.55
CBCT n = 6 0.08 / 0.08 0.34 / 0.32
n = 18 0.23 / 0.22 1.02 / 0.97
CT 0.18 / 0.17 0.28 / 0.27
Accumulative
Risk e = 25y
Dogleg1 0.35% 0.39%
Paraaortic1 0.17% 0.19%
Dogleg2 7.37 8.28
Paraaortic2 3.57 3.89
1 ERR model.
2 EAR model. Value expressed in cases per 10,000 people per year.
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4.4 Discussion
For a total prescription of 20.0 Gy to the paraaortic region, the mean dose measured using
film to the contralateral testis was 0.30 ± 0.08 Gy and 0.31 ± 0.04 Gy with and without
lead shielding, respectively. For the PA region, including the pelvic and ipsilateral common
iliac lymph nodes, and with a prescribed dose of 30.0 Gy, the mean testicular dose was 0.61
± 0.11 Gy and 0.68 ± 0.39 Gy with and without shielding, respectively. Dose reductions up
to 10% were observed with shielding fitted at treatment. This increased to approximately
25% when considering the anterior scrotal dose alone. These doses are approximately two
times the doses previously reported. Bieri et al.19 measured mean doses, using TLDs, of 0.09
Gy (± 0.05 SD) and 0.26 Gy (± 0.12 SD) with and without gonadal shielding, respectively,
for a prescribed dose of 25.2 Gy to the PA region. For the same dose prescribed, only with
dogleg treatment fields, mean doses of 0.55 Gy (± 0.20 SD) and 0.21 Gy (± 0.07 SD) were
measured, without and with shielding, respectively. Similarly, Jacobsen et al.83 reported a
mean dose of 0.32 Gy (± 0.08 SD) to the shielded testis for a delivered dose of 30.0 Gy with
dogleg fields. The contralateral testicle was shielded using a 5 mm lead belt and a 5 cm
thick lead block. The disparity between the doses in this work and those reported may be
due to differences in shielding techniques used and variations in the type and placement of
dosimeters.
Dose reductions to the remaining testis of up to 36% and 78% were recorded with gonadal
shielding fitted at CT and CBCT acquisition respectively.
Despite the relatively large scatter dose from treatment, the accumulative risk of radi-
ation induced cancer to the remaining testis when treating early stage seminoma, with or
without shielding fitted, was found to be 0.4% and 0.2% for dogleg and paraaortic treatment
fields. An additional 7.4 and 8.3 cancers per 10,000 people per year were estimated as a
results of radiotherapy treatment for seminoma with dogleg fields, with and without shield-
ing, respectively. These estimates were 3.6 and 3.9 for paraaortic fields. The risk was found
to decrease with increasing age at diagnosis. Although the risk is low, a greater incidence
of secondary cancers has been reported16,17,84,85. A multicentre investigation involving 839
patients treated with either radiotherapy (758), chemotherapy (76) or surveillance (5) as-
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sessed the significance of second malignancies following treatment for seminoma. Twenty
two second cancers were found, 13 of which were contralateral testicular tumours16. That
is to say, 1.6% of patients developed a testicular second cancer. The median follow-up was
3.9 years. A similar investigation involving 116 patients treated with orchidectomy followed
by radiotherapy revealed 3 subsequent testicular cancers (2.6% of patients)17. The observed
testicular cancer incidence was twice the expected incidence. A third study, with follow-up
periods ranging 5-29 years, observed only 1 (0.8%) second testicular cancer from 128 patients
treated for early stage seminoma84.
The cancer risk associated with diagnostic imaging was found to be less than 0.05%.
The increased risk related to performing daily (18) verses six CBCTs is negligible. The
reported role of diagnostic imaging in cancer induction is conflicted in the literature. van
Walraven et al.86 concluded that the excess risk of second cancers among testicular cancer
survivors is not associated with diagnostic imaging. This population-based study observed
the incidence of second malignancies in 2,569 men who were treated with either surveillance
or chemotherapy for testicular cancer and received 10 CT scans in 5 years after diagnosis.
The median follow-up was 11.2 years. In contrast, a model based study report a lifetime
cancer risk ranging from 1 in 39 to 1 in 85 for a similar surveillance protocol87. Nevertheless,
the majority of diagnostic imaging in this work was CBCT imaging, which based on this
work delivered doses approximately 1/5 of those recorded at CT acquisition.
Radiation is not the only contributing factor to secondary cancers as patients who receive
orchiectomy alone for the treatment of testicular cancer are at increased risk of second cancers
compared to the general population10. Nevertheless, the dose to the remaining testis should
be keep as low as reasonably achievable (ALARA)76, not only to reduce the risk of second
malignancies, but of alternative long term side effects as well. Testicular doses of 0.2-0.7 Gy
result in a temporary reduction in sperm count, returning to normal within 12-24 months88.
While doses above 1.2 Gy indicate permanent testicular damage89.
The risk models used are not without limitations. There was insufficient data to derive
EAR and ERR models for testicular cancer. As such, model parameters for all solid cancers
were used as a best estimate. The competition model74 requires α1 values which are not
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widely available; ICRP nominal risk coefficients were used as an alternative. Moreover, the
competition model is designed to be used with dose volume histogram data to sum the effects
of the dose per volume across the organ at risk. While in this instance, the mean dose to
the whole testicular volume was analysed.
In summary, the risk of radiation induced testicular malignancies is minimal for doses
received while undergoing radiotherapy for seminoma cancer. Still, gonadal shielding should
be fitted to limit unnecessary dose to the testis, thereby reducing radiation-related infertility
and second cancers, regardless of the treatment fields.
4.5 Conclusion
Mean testicular doses of 0.30 ± 0.08 Gy and 0.31 ± 0.04 Gy with and without lead shielding,
respectively, were measured for a prescription of 20 Gy to the paraaortic region. Seminoma
radiotherapy via dogleg fields resulted in respective mean doses of 0.61 ± 0.11 Gy and 0.68
± 0.39 Gy, with and without shielding. The dose to the remaining testis was reduced when
shielding was employed at treatment (10%), planning CT imaging (36%) and pre-treatment
CBCT imaging (78%). The risk of radiation induced second cancers associated with the accu-
mulative dose from treatment and imaging is low; 0.35% and 0.17% for dogleg and paraaortic
treatment fields with shielding and 0.39% and 0.19% without shielding, respectively.
Although radiation is not the only contributing factor to secondary cancers, the dose to
the testis should be limited to minimise this risk and other long term complications, such as
infertility. This can be achieved by using appropriate gonadal shielding, irrespective of the
treatment fields employed.
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Chapter 5
Case Study 2: Breast Cancer
5.1 Introduction
Breast cancer is the most common female cancer in the world, accounting for 22.9% of
all incidences. It is most commonly found in postmenopausal woman, but can occur at any
age77. The treatment prescribed depends on the type of disease and clinical staging in accor-
dance with the International Union Against Cancer (UICC) Tumour, Nodes and Metastases
(TNM) classification. Radiotherapy following surgery reduces the risk of recurrence at five
years post treatment from 26% to 7%90 and aids local disease control90–92. As such, breast
conserving surgery or mastectomy with adjuvant radiotherapy to the whole breast or chest
wall, respectively, is the standard care path, followed by chemotherapy and/or endocrine
therapies as required. For over several decades breast cancer has been treated with tangen-
tial fields, limiting unnecessary dose to the heart and lungs. Dose uniformity is aided by
physical wedges, which were later superseded by dynamic wedges. Currently, more conformal
techniques, such as forward planned IMRT, have been adopted as the standard in planning
breast volume tangential irradiation. The prognosis of breast cancer is good if treated in the
early stages of the disease, with a 5 year relative survival rate of 98.4%. This decreases to
83.9% for regional disease at diagnosis93. However, the risk of radiation induced cancer and
late side effects, such as cardiac toxicity and pneumonitis, remain94. Although the radiation
treatment is conformal to the diseased breast, healthy tissue will receive dose from internal
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radiation scatter, collimator scatter and radiation leakage through the head of the treatment
machine. Additionally, the normal tissue will receive dose contributions from planning CT
and pretreatment imaging. The lungs95,96, heart96–98 and contralateral breast21,22 are the
surrounding organs most commonly assessed in breast cancer radiotherapy and the dose re-
ceived is well known. The dose to the thyroid from early stage breast cancer radiotherapy
is rarely measured as it lies away from the treatment field, however, hypothyroidism after
loco-regional breast cancer radiotherapy has been seen although the link between the two
is debated99,100. Based on a retrospective cohort study, Huang et al. showed that the risk
of radiation-associated thyroid carcinoma following radiotherapy for breast carcinoma is un-
dectectable101. Although the contralateral breast dose from therapy and imaging for breast
carcinoma has been assessed independently, to the author’s knowledge, the total combined
dose to the radiosensitive contralateral breast and thyroid has not been evaluated to date.
In this work, dose contributions from imaging modalities, CT and cone-beam CT (CBCT),
and treatment were measured and the risk of radiation induced cancer assessed.
5.2 Materials and Methods
The dose to the contralateral breast and thyroid was measured on an anthropomorphic
phantom using Gafchromic film and TN-1002RD MOSFET dosimeters and compared to that
predicted by the TPS. Treatment was planned using Pinnacle3 (collapsed cone convolution
algorithm and 4 mm dose grid) and delivered on a Varian iX linear accelerator (Varian
Medical Systems, Palo Alto, CA) equipped with On-Board Imager R© (v1.4) and having CBCT
capability. Risk models (Chapter 3) were used to calculate the possible risk of second cancers
due to breast radiotherapy.
5.2.1 Treatment Planning Techniques
The contralateral breast dose has been studied by many authors using humanoid phantoms
fitted with commercial breast moulds (see e.g. RANDO R© Phantoms, The Alderson Radia-
tion Therapy Phantom), though these do not accurately represent the typical breast tissue
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distribution of a patient on the treatment couch. To overcome this, a human model was
used to create wax breast moulds to fit an anthropomorphic phantom, Rando, replicating
the typical patient of cup size C and breast separation 22 cm. These moulds were separate
and fixed with tape for each use as required. All future references to Rando assume the
breast moulds were fitted unless stated otherwise. Eight measurement points were identified
on the surface of the contralateral breast, marked with tape and the centre crossed with
pen: three at each of 2.5 cm and 12 cm from midline, at displacements of 5, 10 and 15
cm from the superior border, respectively and two on the lateral edge of the breast at 10
and 15 cm from the superior field edge, keeping in line with the other measurement points.
The points identified are shown in Figure 5.1. One measurement point was selected at the
position of the thyroid on the surface of the phantom. External fiducial markers were affixed
in order to locate the measurement points on the CT scan. Rando was positioned supine on
a MEDTEC Breastboard (elevation notch 4, head rest 1, notch 3), scanned on a Siemens
Somatom Sensation Open CT Scanner as per departmental protocol (120 kV, 96 mA, 3 mm
slice thickness) and the data set was exported to Pinnacle3 for planning.
Figure 5.1: Rando positioned on the breast board with the wax breast moulds fitted. MOS-
FETs are positioned on the nine measurement points; eight on the contralateral breast (green
squares) and one at the position of the thyroid.
The right breast volume was delineated, keeping within 0.5 cm of the external and ipsi-
lateral lung contours. In order to compare the dose from different treatment techniques and
energy modalities, five breast plans were created, namely, 6MV and 10MV Step and Shoot
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(S&S), 6MV and 10MV Enhanced Dynamic Wedge (EDW) and 6MV physical wedge (PW).
Planning with physical wedges using a 10MV beam was not commissioned in our depart-
ment. All plans were designed by the author following departmental protocol and consisted
of parallel opposed isocentric tangential fields treating the right breast with a prescribed
dose of 45 Gy in 25 fractions. An open field 12 cm wide and 25 cm long was used across all
beams and plans. The anterior edge of the field extended 2 cm beyond the breast tissue to
compensate for breathing motion. The field length extended inferiorly from the suprasternal
notch to 2 cm below the breast. Due to the necessary length of the field, a half beam block
arrangement was used in all plans except PW. The X-jaws have a maximum traverse of 10
cm when an external wedge is fitted, thus both X-jaws were open to produce the desired
volume coverage. The superior and posterior beam edges were matched using Casebow prin-
ciples102 resulting in couch angulations 3◦ and 357◦ for lateral and medial tangent beams,
respectively. The weighting of the medial and lateral beams was almost equivalent in each
treatment plan.
The contralateral breast volume was contoured to mimic the treatment volume and further
subdivided into eight regions (see Figure 5.2b), each orientated around a fiducial marker.
The three medial regions were identified sub-volumes 1-3, with one being the most superior.
Sub-volumes 4-6 represent the middle three regions and 7 and 8 the lateral regions, with
eight being the inferior region. The volume of each sub-volume, extracted from the treat-
ment planning system, is given in Table 5.1. The thyroid was delineated with a resulting
volume of 3.9 cm3.
Table 5.1: The volumes of the contralateral breast sub-regions.
Contralateral Breast Sub-volumes
Region 1 2 3 4 5 6 7 8
Volume (cm3) 101.1 152.0 131.4 123.5 271.9 183.4 212.2 117.3
Physical wedge pair planning
6MV photons were prescribed in four fields, two medial and two laterals, to achieve the
desired 95% coverage of the target volume. Approximately 90% of the dose was delivered
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(a) Skin surface render of the breast phantom. (b) DRR depicting the sub-volumes.
Figure 5.2: An illustration of the breast volume sub-divided in comparison with the skin
surface.
through 15◦ wedged beams. The remaining dose was delivered through segmented fields
which were added to shield hotspots and reduce the dose gradient across the volume. These
fields used Multileaf Collimation (MLCs) to block areas of high dose and delivered a minimum
of 10 Monitor Units (MU).
Enhanced dynamic wedge pair planning
The EDW technique simulates a physical wedge by moving one of the Y-jaw collimators from
an open field to within 0.5 cm of the opposing jaw. The dose rate and speed at which the jaw
moves vary to imitate assorted wedge angles. This technique reduces the time the patient
is on the couch as radiation therapists do not need to enter the room to physically change
wedges and results in less dose to the contralateral breast103,104. EDWs of 15◦ and 10◦ were
prescribed on the medial and lateral tangents when planning with a 6MV beam while 10◦
for both 10MV fields. Additional unwedged segments were added to reduce hotspots in both
plans with a minimum deliverance of 10MU. The collimator was rotated to 90◦ to facilitate
this treatment technique.
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Step and Shoot IMRT planning
For this forward planned treatment technique MLC fields (commonly known as control
points) are added to improve the homogeneity of the dose distribution across the treat-
ment volume. MLCs are shaped to isodoses of the relevant open field beam to shield areas
of excessively high dose. A maximum of four control points were used. Each control point
delivered a minimum of 5MU with at least 80% of the total beam dose delivered through the
open field, as per departmental protocol. S&S plans were created using both 6 and 10MV
beams.
Figure 5.3 displays the resulting isodose distributions at the zero slice (CT reference) for
the five treatment plans developed. The pink and red isodose lines represent the 95 and
100% dose coverage, respectively.
(a) SS 6MV (b) SS 10MV (c) EDW 6MV
(d) EDW 10MV (e) PW 6MV
Figure 5.3: Isodose distribution on the zero slice (CT reference) for the five breast plans.
The pink and red isodose lines represent the 95 and 100% dose coverage, respectively.
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5.2.2 Measurements
Planning CT
Rando was positioned on the CT scanner bed using the established breast board and head
rest settings and aligned with the in-room lasers. Eight MOSFETs were placed centrally
at the predetermined positions on the surface of the contralateral breast and secured with
tape. One MOSFET was taped at the level of the thyroid on the ’skin’ surface. A lateral
topogram was carried out followed by a CT scan as per departmental protocol, extending
from the lower mandible to the mid-abdomen. The MOSFETs were read out within five
minutes following the CT scan. Two repeat measurements were taken, allowing at least five
minutes between consecutive CT scans. 3 x 3 cm2 XR-QA2 Gafchromic film squares were
taped at the same locations, with a 4 x 4 cm2 square positioned between phantom slices
at the level of the thyroid. All film pieces were marked to ensure the original orientation
was maintained. The tape did not encroach more than 0.5 cm when securing the film edges.
The same scanning technique was used and a total of three measurements were performed.
The film was scanned 46 hours post irradiation and analysed as previously described with
the exception of the thyroid measurement films, for which the mean dose to a horseshoe-like
area mimicking the thyroid was evaluated. The area, shown in Figure 5.4, is 3 cm along the
x- and y-axis.
Cone-Beam Computed Tomography
Rando was positioned on the treatment couch and aligned with the lasers at the CT reference.
Of the three couch shifts to the treatment isocentre, only the superior shift could be carried
out, thus preventing couch collisions with the CBCT 360◦ gantry arc. However, this is not
a method of best practice as applying couch shifts after imaging to ensure accurate patient
positioning can introduce treatment errors. With the half bowtie filter fitted Low-dose thorax
CBCT images, using the standard imaging protocol (110 kVp, 20mA, 20ms), were acquired;
three with MOSFETs and three with XR-QA2 Gafchromic film positioned as previously
described (section 5.2.2). The field length was 16 cm and encompassed sub-volumes 1, 2, 4,
5 and 7.
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(a) Delineated thyroid contour in the
TPS.
(b) Area of film used for analysis.
Figure 5.4: The horseshoe-like area used for film analysis of the thyroid measurements. The
shape is comparable with the delineated thyroid in the TPS.
Treatment
Following CBCT, the remaining lateral and vertical shifts to the treatment isocentre were
made. The dose to the contralateral breast and thyroid from a single fraction of each
treatment technique was measured, first with EBT2 Gafchromic film. The film size and
placement was consistent with previous measurements. A total of three measurements were
made for each treatment technique. This was repeated using MOSFET dosimeters. The
MOSFET readings were recorded after each fraction and the film was digitised 1 day later,
keeping in agreement with the MV film calibration.
5.2.3 Pinnacle3 Dose
In the TPS, the density of the metal fiducial markers was overridden to 0 g/cm3 to avoid
interference with the dose distribution at the surface of the phantom. Points of interest
(POIs) were created directly below the reference fidicial markers on the contralateral breast
and at the level of the thyroid for comparison with dose measured using Gafchromic film. For
comparison with MOSFET dosimeters, POIs were created 1 mm below the first set of points
to compensate for the inherent build of the MOSFETs due to the epoxy layer. The dose was
recorded at each POI and at five surrounding points located 2 mm inferior, superior, posterior
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and lateral (two points) of the POI, respectively. The dose was not recorded anteriorly as
this point was in air. For each treatment plan, the mean of the six point doses was compared
to the measured doses. Additionally, the mean dose to the thyroid volume was extracted
from the TPS dose volume histogram (DVH) data.
5.2.4 Risk Analysis
The risk of radiation induced cancer in the thyroid and contralateral breast were assessed
using an array of models previously described (Chapter 3). The competition risk model
was employed for doses from both treatment and imaging, while the ERR and EAR models
were used to assess only CT and CBCT doses. For the competition model, an α/β ratio of
3.4 Gy (2.3, 4.5 95% CI) was used to assess late effects of normal breast tissue105,106 and a
generalised α/β ratio for late responding tissue of 3 Gy was assumed for the thyroid. The risk
coefficients, α1 breast = 0.011 Gy
-1, α1 thyroid = 0.003 Gy
-1 and α2 = 0.25 Gy
-2 were assumed,
resulting in β1 breast, β2 breast, β1 thyroid and β2 thyroid values of 3.24x10
−3, 0.07, 1x10−3 and
0.08, respectively74,76. The tissue volumes are given (section 5.2.1).
Specific parameters are given in the BEIR VII Phase II report75 for modelling female
breast and thyroid cancer risks. For the given ERR parameters β = 1.05 (0.28, 3.9 95% CI),
γ = -0.83 and η = 0, the thyroid cancer risk in females is given by:
ERR = D 1.05 exp[−0.083(e− 30)]
The ERR model, with β = 0.51 (0.28, 0.83 95% CI), γ = 0 and η = -2.0, results in the risk
of female breast cancer:
ERR = D 0.51 (α/60)−2
For the given parameters β = 9.4 (6.7, 13.3 95% CI), γ = -0.51 and η = 1.1, the EAR for
female breast cancer is given by:
EAR = D 9.4 exp[−0.05(e− 30)](α/60)1.1
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These models were evaluated for exposed ages, e = 40 and 50 years and attained ages 20
years later, α = 60 and 70 years.
The risk of radiation induced cancer due to CBCT was assessed for two common imaging
schemes: daily (n=25) and imaging the first three days followed by weekly CBCT (n=7).
The CT associated risk was calculated assuming only one CT was performed.
5.3 Results
5.3.1 CT & CBCT Imaging
The mean dose recorded (95% CI) from CBCT and CT acquisition is given in Table 5.2.
The dose to the contralateral breast from CT imaging is approximately uniform across the
volume. This is to be expected due to the helical nature of the image acquisition. Similar
results were seen within the imaging field for 360◦ CBCT. Contralateral breast sub-volumes
3, 6 and 8 were outside of the imaging field for CBCT acquisition and this is reflected in the
results. The MOSFET signal at CBCT is poor due to the low X-ray tube current and the
attenuation of the epoxy bulb.
Table 5.2: Breast Imaging dose recorded from a single CBCT and CT scan.
Imaging Dose (cGy)
CBCT CT
Region MOSFET XR-QA2 MOSFET XR-QA2
Thyroid 0.09 ± 0.18 0.34 ± 0.04 1.18 ± 0.13 1.94 ± 0.14
1 0.27 ± 0.33 1.18 ± 0.01 0.77 ± 0.34 1.74 ± 0.05
2 0.10 ± 0.11 1.15 ± 0.04 1.00 ± 0.38 1.95 ± 0.12
3 0.00 ± 0.00 0.34 ± 0.02 1.51 ± 0.67 2.50 ± 0.11
4 0.57 ± 0.29 1.08 ± 0.02 0.82 ± 0.26 1.45 ± 0.06
5 0.49 ± 0.21 1.00 ± 0.01 0.31 ± 0.20 1.90 ± 0.09
6 0.04 ± 0.08 0.24 ± 0.07 1.28 ± 0.81 2.14 ± 0.13
7 0.47 ± 0.15 0.94 ± 0.01 1.27 ± 0.52 1.61 ± 0.20
8 0.00 ± 0.00 0.31 ± 0.02 1.12 ± 0.28 2.01 ± 0.29
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5.3.2 Treatment Delivery
The mean of the three single fraction deliveries and the associated uncertainty of the mean
(95% CI) were calculated. The dose to the sub-volumes of the contralateral breast and thy-
roid from the five respective plans are tabulated for film (Table 5.3) and MOSFET dosimeters
(Table 5.4) and represented graphically in Figure 5.5. The maximum dose measured is ex-
pressed as a percentage of the prescribed dose (Table 5.3 and 5.4 for film and MOSFETs,
respectively). The highest dose was recorded at the three points closest to the treatment field
for all treatment techniques, as expected. The physical wedge plan resulted in the largest
dose to the contralateral breast and thyroid which is in agreement with reported studies.
This is due to the increased scatter from the physical wedge.
Table 5.3: The total dose to the thyroid and contralateral breast as mea-
sured using EBT2 film. The total dose was calculated from the measured
dose in a single fraction multiplied by the number of fractions (n = 25).
The mean of three measurements (95% CI) is recorded and the maximum
dose a sub-volume received is given (max dose). Regions 1-8 represent the
contralateral breast sub-volumes.
Treatment Delivery Concomitant Dose (Gy) - film
Region SS 6MV SS 10MV EDW 6MV EDW 10MV PW
Thyroid 0.50 ± 0.21 0.68 ± 0.28 0.73 ± 0.14 0.47 ± 0.43 1.00 ± 0.16
1 4.47 ± 0.37 3.46 ± 0.11 4.29 ± 0.14 4.00 ± 0.08 4.56 ± 0.02
2 4.55 ± 0.32 3.51 ± 0.56 3.82 ± 0.27 4.44 ± 0.06 4.65 ± 0.17
3 3.38 ± 0.17 2.55 ± 0.11 2.06 ± 0.45 3.21 ± 0.39 3.63 ± 0.21
4 1.33 ± 0.23 1.01 ± 0.16 2.08 ± 0.30 2.01 ± 0.03 2.59 ± 0.22
5 1.47 ± 0.25 1.08 ± 0.35 1.83 ± 0.29 1.80 ± 0.37 2.67 ± 0.09
6 1.11 ± 0.12 0.88 ± 0.12 1.24 ± 0.09 1.35 ± 0.19 2.09 ± 0.09
7 0.34 ± 0.31 0.50 ± 0.16 0.78 ± 0.16 0.93 ± 0.33 0.94 ± 0.17
8 0.24 ± 0.18 0.28 ± 0.18 0.51 ± 0.31 0.54 ± 0.27 0.56 ± 0.17
Max dose 4.55 (10.1%) 3.51 (7.8%) 4.29 (9.5%) 4.44 (9.9%) 4.65 (10.3%)
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Table 5.4: The total dose to the thyroid and contralateral breast as mea-
sured using MOSFET dosimeters. The total dose was calculated from the
dose reading in a single fraction multiplied by the number of fractions (n
= 25). The mean of three measurements (95% CI) is recorded and the
maximum dose a sub-volume received is displayed (max dose). Regions
1-8 represent the contralateral breast sub-volumes.
Treatment Delivery Concomitant Dose (Gy) - MOSFET
Section SS 6MV SS 10MV EDW 6MV EDW 10MV PW
Thyroid 0.93 ± 0.32 1.42 ± 0.51 1.84 ± 0.16 1.09 ± 0.14 1.82 ± 0.18
1 2.64 ± 0.11 2.95 ± 0.40 0.74 ± 1.31 3.99 ± 0.33 4.96 ± 0.06
2 2.73 ± 0.08 2.93 ± 0.21 2.47 ± 0.17 3.78 ± 0.12 3.79 ± 0.19
3 2.00 ± 0.10 1.45 ± 0.12 1.09 ± 0.03 2.09 ± 0.58 3.12 ± 1.03
4 0.51 ± 0.36 0.49 ± 0.25 1.31 ± 0.19 1.40 ± 0.10 2.12 ± 0.15
5 0.73 ± 0.80 0.20 ± 0.36 0.97 ± 0.48 0.78 ± 0.30 1.63 ± 0.22
6 0.20 ± 0.12 0.40 ± 0.11 0.67 ± 0.05 0.24 ± 0.14 2.06 ± 0.34
7 0.17 ± 0.08 0.00 ± 0.00 0.15 ± 0.27 0.28 ± 0.26 0.39 ± 0.37
8 0.06 ± 0.11 0.14 ± 0.09 0.00 ± 0.00 0.00 ± 0.00 0.16 ± 0.12
Max dose 2.73 (6.1%) 2.95 (6.6%) 2.47 (5.4%) 3.99 (8.9%) 4.96 (11.0%)
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Figure 5.5: A comparison between the measured doses to the normal tissue volumes from the
five treatment techniques: (a) EBT2 film and (b) MOSFETs. The recorded doses decrease
with increasing distance from the treatment field. Normal tissue volumes 1-8 correspond to
the contralateral breast sub-volumes.
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The dose to the points of interest (95% CI) and the mean DVH thyroid dose extracted
from Pinnacle3 are given in Table 5.5. The TPS dose and the measured doses for each
treatment technique are compared in Figure 5.6 and 5.7.
Table 5.5: The POI doses predicted in the TPS to the normal tissue volumes over
the course of treatment. Dose to the surface of the phantom and at 1 mm depth are
given. The DVH mean dose to the thyroid (DVHmean) volume is given. Points 1-8
correspond to the contralateral breast sub-volumes with the same numbering.
Pinnacle3 Dose (Gy)
Region Point Depth SS 6MV SS 10MV EDW 6MV EDW 10MV PW
DVHmean - 0.34 0.21 0.31 0.20 0.53
Thyroid
surface 0.48 ± 0.06 0.30 ± 0.04 0.37 ± 0.07 0.36 ± 0.01 0.87 ± 0.03
1 mm 0.51 ± 0.03 0.33 ± 0.02 0.43 ± 0.03 0.39 ± 0.01 0.93 ± 0.01
1
surface 1.22 ± 0.05 1.14 ± 0.05 1.77 ± 0.04 1.21 ± 0.26 1.46 ± 0.24
1 mm 1.32 ± 0.03 1.02 ± 0.05 1.73 ± 0.03 1.46 ± 0.03 1.86 ± 0.03
2
surface 0.85 ± 0.28 0.78 ± 0.13 1.24 ± 0.24 1.33 ± 0.15 1.69 ± 0.24
1 mm 1.17 ± 0.15 0.95 ± 0.06 1.67 ± 0.08 1.64 ± 0.03 2.06 ± 0.03
3
surface 0.97 ± 0.04 0.40 ± 0.12 1.05 ± 0.23 0.99 ± 0.10 1.21 ± 0.11
1 mm 0.92 ± 0.02 0.57 ± 0.03 1.25 ± 0.05 1.21 ± 0.02 1.44 ± 0.01
4
surface 0.10 ± 0.02 0.08 ± 0.01 0.20 ± 0.01 0.09 ± 0.02 0.14 ± 0.03
1 mm 0.11 ± 0.01 0.10 ± 0.01 0.22 ± 0.01 0.11 ± 0.02 0.16 ± 0.02
5
surface 0.14 ± 0.02 0.12 ± 0.01 0.25 ± 0.01 0.12 ± 0.03 0.23 ± 0.02
1 mm 0.17 ± 0.00 0.14 ± 0.00 0.28 ± 0.00 0.16 ± 0.03 0.24 ± 0.01
6
surface 0.04 ± 0.01 0.04 ± 0.01 0.14 ± 0.02 0.13 ± 0.01 0.06 ± 0.02
1 mm 0.06 ± 0.01 0.05 ± 0.01 0.14 ± 0.05 0.14 ± 0.01 0.08 ± 0.02
7
surface 0.09 ± 0.01 0.04 ± 0.01 0.08 ± 0.01 0.04 ± 0.01 0.08 ± 0.01
1 mm 0.09 ± 0.01 0.05 ± 0.01 0.09 ± 0.01 0.03 ± 0.01 0.08 ± 0.01
8
surface 0.05 ± 0.02 0.04 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 0.05 ± 0.02
1 mm 0.06 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 0.04 ± 0.02
The film most often reads higher than the MOSFETs, with the variance increasing with
increasing distance from the treatment field. Across the five plans, the average MOSFET
dose was 71, 51 and 29% of the film dose for the medial, middle and lateral sub-volumes,
respectively. The PW plan shows the best agreement between MOSFET and film measure-
ments (76%), while 6MV EDW shows the worst at 42%. However, the disparity between
MOSFET and film results was ≤ 4.5 cGy for the middle and lateral sub-volumes. For the
thyroid, a direct comparison can not be made between MOSFET and film measurements as
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the MOSFETs were placed on the phantom surface while the films were placed at depth and
parallel to the incident beam. However, the results are in the same order of magnitude.
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Figure 5.6: A comparison between MOSFET, Gafchromic film and TPS dose to the normal
tissue volumes from 6MV treatment techniques. Normal tissue volumes 1-8 correspond to
the contralateral breast sub-volumes.
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Figure 5.7: A comparison between MOSFET, Gafchromic film and TPS dose to the normal
tissue volumes from 10MV treatment techniques. Normal tissue volumes 1-8 correspond to
the contralateral breast sub-volumes.
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5.3.3 Risk Analysis
The risk of radiation induced cancer due to the accumulative dose to healthy tissue a patient
receives while undergoing treatment was calculated based on a worst case scenario, i.e., the
Gafchromic film measurements were used. The maximum dose received during CT and
CBCT acquisition was assessed when using the ERR and EAR risk models and the risk
was evaluated for 20 years post exposure and based on the assumption that the patient
was treated at either 40 or 50 years of age (e = 40, 50y, attained age α = 60, 70y). The
accumulative risk, with contributions from CT, CBCT and treatment, was determined based
on the competition model risk estimates. The calculated risks are given in Table 5.6. In
summary, the risk of radiotherapy to the breast causing cancer in the contralateral breast,
as determined using the competition model, is approximately 1.2% averaged over all cases
and 0.2% for inducing thyroid carcinoma.
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Table 5.6: Radiation induced contralateral breast and thyroid cancer risk
estimates using the competition, ERR and EAR risk models. EAR and ERR
were calculated at 20 years post treatment for age at treatment of 40 or 50
years (e = 40, 50y and α = 60, 70y). The results are given as 40y / 50y. A
worst case scenario was assumed by using the maximum doses delivered at
CT and CBCT acquisition. The accumulative risk from CT, daily CBCT and
treatment is considered.
Radiation Induced Cancer Risk Estimates
Risk Model Radiation Source Cancer site
Contralateral Breast Thyroid
Competition
Model
Treatment SS 6MV 1.04% 0.15%
SS 10MV 0.98% 0.19%
EDW 6MV 1.18% 0.20%
EDW 10MV 1.23% 0.14%
PW 1.34% 0.26%
CBCT n = 7 0.069% 0.008%
n = 25 0.210% 0.028%
CT 0.021% 0.006%
ERR (40y / 50y)
CBCT n = 7 0.048% / 0.035% 0.011% / 0.005%
n = 25 0.171% / 0.124% 0.039% / 0.017%
CT 0.013% / 0.009% 0.009% / 0.004%
EAR (40y / 50y)1
CBCT n = 7 0.53 / 1.37 -
n = 25 1.91 / 0.38 -
CT 0.14 / 0.10 -
Accumulative
Risk
SS 6MV 1.07% 0.15%
SS 10MV 1.01% 0.19%
EDW 6MV 1.20% 0.20%
EDW 10MV 1.25% 0.14%
PW 1.36% 0.26%
1 EAR expressed in cases per 10,000 people per year.
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5.4 Discussion
The calculated accumulative risk of radiation induced cancer to the contralateral breast
when treating early stage breast carcinoma was found to be 1.2% (range 1.1 - 1.4%). This
risk estimate takes into consideration the dose from treatment, imaging for planning and
pretreatment imaging. Treatment delivery using physical wedges resulted in the nominally
greatest risk, 1.4%. For a prescribed dose of 45 Gy in 25 fractions, the higher doses were
measured at the points closest to the treatment field, with the maximum dose to the con-
tralateral breast of 4.55 ± 0.32, 3.51 ± 0.56, 4.29 ± 0.14, 4.44 ± 0.06 and 4.96 ± 0.06 Gy
for SS 6MV, SS 10MV, EDW 6MV, EDW 10MV and PW treatment delivery, respectively.
These doses correspond to 10.1%, 7.8%, 9.5%, 9.9% and 11.0% of the prescribed treatment
dose and are in agreement with doses previously reported. Prabhakar et al.4 investigated
the contralateral breast surface dose due to wedged (physical and dynamic) and unwedged
6MV tangential fields using MOSFET detectors and reported doses of up to 15.3% with 60◦
physical wedges fitted. Dose conformity using 15◦ physical and enhanced dynamic wedges
resulted in maximum surface doses of 10.5% and 9.8%, respectively. Johansen et al.23 em-
ployed DVH analysis to assess the dose to the contralateral breast for 16 patients treated
with 50 Gy in 2 Gy fractions using tangential fields. The mean of the maximum contralateral
breast doses for the 16 patients was 5.4 Gy (10.8%). Bhatnagar et al.5 reported surfaces
doses of 7.7% of the prescribed dose using thermoluminescent dosimeters positioned on the
patient’s contralateral breast, 4 cm from the centre of the medial border of the tangent field.
Mean doses to the contralateral volume of 0.3 - 3.0 Gy have been reported23–25.
Several studies have assessed the role of radiation treatment in the development of con-
tralateral breast cancer. A cohort study evaluating 529 contralateral breast cancers which
developed at least 8 years after initial breast cancer diagnosis, with an average patient ex-
posure age of 51 years and an estimated mean contralateral breast dose of 2.51 Gy, found
little risk of radiation induced breast cancer for an age of first treatment 50+ years107. An-
other study evaluated 655 cases of second breast cancer with an estimated mean dose to
the contralateral breast of 3.02 Gy. The association between contralateral breast cancer and
radiotherapy was minimal, however, for patients less than 44 years of age at initial diagnosis,
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a stronger correlation was observed. The incidence of second cancers was not linked to ra-
diotherapy for treatment age 45+ years. Boice et al.24 concluded that the risk of secondary
breast cancer due to radiotherapy is largely dependent on age at treatment.
The contralateral breast cancer risk associated with daily CBCT was 0.2%, which was
reduced by approximately 1/3 when the alternative pretreatment imaging protocol was as-
sumed (image the first three days and then weekly). For the Low Dose Thorax standard
imaging protocol, surface dose measurements using XR-QA2 film, made within the imag-
ing field, ranged 0.94 - 1.18 cGy. This is comparable to the dose, ranging 0.65 - 0.95 cGy,
measured by Ueltzho¨ffer et al.25 using an ionisation chamber. Despite the low risk, imaging
parameters, such as gantry start and stop angle, mA and kVp, can be optimised to further
reduce the dose to the healthy tissue while maintaining adequate image quality25. An an-
nual increase of 1.9 breast cancers per 10,000 people receiving daily CBCT (n = 25) and
0.1 breast cancers per 10,000 breast CT scans was estimated. This equates to an annual
increase of 1 breast cancer per 70,000 breast CT scans.
Concomitant dose of up to 1.0 Gy was measured at the thyroid from treatment delivery.
Thyroid doses of 0.3 and 1.9 cGy per scan were recorded for CBCT and CT, respectively.
However, the risk of thyroid cancer as a result of radiotherapy and the associated imaging
for breast carcinoma was found to be negligible, 0.2% (range 0.1 - 0.3%). Huang et al.101,
in a retrospective population based study, identified 194,798 women diagnosed with breast
cancer, of which 48,495 were treated with radiotherapy. 140 subsequent thyroid cancers
developed (28 in the group treated with radiotherapy) with a follow up of at least 10 years.
Nevertheless, no significant increase in the risk of thyroid cancer was observed for patients
treated with radiation therapy compared to those not having received radiotherapy and the
general population. Similarly, no increased incidence of radiation related secondary thyroid
cancer was observed in a cohort study involving 64,782 women who underwent surgery for
breast carcinoma, of which 33,763 received adjuvant radiotherapy108. Although radiotherapy
for breast cancer is not associated with the risk of thyroid cancer, an increased prevalence of
thyroid disease, such as nontoxic goiter and Hashimoto’s thyroiditis, has been observed100,109.
The risk of thyroid dysfunction following radiotherapy is related to the volume of the thyroid
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irradiated99.
There are several limitations in the approach used to estimate the risk of second ma-
lignancies. One limitation is the availability of the coefficients required for the competition
model74. α/β ratios are based on clinical studies and vary depending on treatment dose,
treatment fractionation regime and stipulated end points. However, more significantly, the
model requires α1 values which are difficult to come by. In this study, ICRP nominal risk
coefficients were used as a best estimate. Additionally, the competition model is intended
to be used with dose volume histogram data to sum the effects in each dose interval across
the volume of concern. A slightly different methodology was used in this work; the sum of
the effect in each delineated sub-volume was calculated. Furthermore, EAR and ERR model
parameters are largely based on pooled analysis population studies of atomic bomb survivors
and as such, the beneficial effects of fractionation are not accounted for.
In summary, the risk of radiation induced contralateral breast and thyroid cancer, fol-
lowing doses received while undergoing radiotherapy for breast carcinoma, was found to
be minimal. Treatment delivery using physical wedges for dose conformity resulted in the
highest second cancer risk.
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5.5 Conclusion
Maximum contralateral breast doses of 4.55 ± 0.32, 3.51 ± 0.56, 4.29 ± 0.14, 4.44 ± 0.06
and 4.96 ± 0.06 Gy were measured for SS 6MV, SS 10MV, EDW 6MV, EDW 10MV and
PW treatment delivery, respectively. These doses correspond to 10.1%, 7.8%, 9.5%, 9.9%
and 11.0% of the prescribed treatment dose. The risk of contralateral breast malignancies
following radiation exposure due to breast imaging and treatment, was found to be 1.1 -
1.4%, with treatment delivery using physical wedges resulting in the greatest risk. The
associated risk of thyroid carcinoma was trivial (0.1 - 0.3%).
Nevertheless, the ALARA76 principle should be adopted when implementing pretreat-
ment imaging protocols and when considering alternative treatment techniques for dose
conformity, thereby reducing the dose to healthy tissue surrounding the target volume and
consequently, unnecessary side effects.
63
Chapter 6
Discussion and Conclusions
6.1 Discussion
The aim of this work was to assess the risk of radiation induced secondary malignancies to
normal tissue lying out of the treatment field for patients who are treated at a relatively
young age and whose primary cancer treatment has a good prognosis, thus accounting for
the time delay for radiation induced cancers to occur. The risk of thyroid and contralateral
breast carcinoma from early stage breast radiotherapy and the risk of contralateral testic-
ular carcinoma from seminoma radiotherapy were investigated. The dose to healthy tissue
from imaging for planning, pretreatment imaging and treatment related scatter was mea-
sured using MOSFET detectors and Gafchromic film. To the author’s knowledge this is the
first work to compare Gafchromic film and MOSFET dosimeters for investigating the total
concomitant treatment related dose and associated risk.
For seminoma cancer radiotherapy, dose to the contralateral testis was measured result-
ing from a prescribed dose to the paraaortic region including the ipsilateral and common
iliac lymph nodes and that to the paraaortic region only. Additionally, dose with and with-
out gonadal shielding was assessed. The mean dose to the contralateral testis for a total
prescription of 20.0 Gy to the paraaortic region was 0.30 ± 0.08 Gy and 0.31 ± 0.04 Gy with
and without lead shielding, respectively. For a prescribed dose of 30.0 Gy to the extended PA
region, the mean testicular dose was 0.61 ± 0.11 Gy and 0.68 ± 0.39 Gy with and without
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shielding, respectively. These doses are slightly higher than those previously reported19,83,
nevertheless, the accumulative risk of radiation induced cancer, taking into consideration all
imaging and treatment related dose and the use of gonadal shielding, was found to be 0.4%
and 0.2% for dogleg and paraaortic treatment fields. These risks are approximately 4 - 13
times less than the secondary testicular cancer incidence reported in the literature16,17,84,85.
The dose to the contralateral breast was measured for five different treatment techniques,
with a maximum measured dose of 4.55 ± 0.32, 3.51 ± 0.56, 4.29 ± 0.14, 4.44 ± 0.06 and
4.96 ± 0.06 Gy for SS 6MV, SS 10MV, EDW 6MV, EDW 10MV and PW treatment delivery,
respectively. Doses of up to 11% of the prescribed treatment were measured near the edge
of the treatment field, which is in agreement with previously reported measurements4,5, 23.
The calculated approximate accumulative risk of radiation induced cancer to the CB when
treating early stage breast carcinoma was found to be 1.1 - 1.4%, depending on the treatment
technique used.
Concomitant dose of up to 1.0 Gy was measured at the thyroid from radiotherapy treat-
ment for early stage breast carcinoma. Thyroid doses of 0.3 and 1.9 cGy per scan were
recorded for CBCT and CT, respectively. Nevertheless, the resulting accumulative risk of
thyroid cancer was found to be negligible, 0.2%.
6.2 Limitations of the Approach
There are several limitations in the methodology used in this work including, but not limited
to, the availability of risk model parameters and the uncertainty of the energy spectrum in
the periphery of the treatment fields.
The competition risk model requires model parameter α1 which is not easily obtainable
in the literature. Consequently, ICRP nominal risk coefficients were used as a suitable
alternative. Additionally, the competition model is designed to be used with dose volume
histogram data from the treatment planning system to sum the effects of the dose per volume
across the organ at risk, whereas, in this work, measured organ at risk doses to specified
volumes were used. The excess relative risk and excess absolute risk model parameters
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were not available for testicular cancer risk assessment and as such model parameters for all
solid cancers were used as a best estimate. Furthermore, the EAR and ERR models do not
account for fractionation in treatment regimes.
The energy spectrum of peripheral dose has been investigated by several authors62,110–112
and is dependent on beam energy, field size, distance from the field edge and linear accelerator
model. Although EBT2 Gafchromic film and MOSFET detectors demonstrate little energy
dependence in the MV energy range47,56, internal scatter, which is a major contributor to
the dose in the near periphery of treatment fields, has energy spectral peaks near 500 keV
for 6 and 15 MV beams62. EBT2 film is designed for use in beams of energy down to 50
keV, however, small variations in the chemical composition of the film which occur over
time can result in large over- or under responding of the film113. Future work would include
determining the energy spectrum of the scatter at the radiosensitive organs lying out of
the treatment field in order to accurately calibrate the dosimeters intended to measure the
scatter dose.
TN-1002RD MOSFETs and Gafchromic film were found to be suitable dosimeters for
measuring dose in the kV and MV range. The accuracy of MOSFET measurements decrease
at distances > 5 cm from the treatment field, i.e. regions of low dose. The reproducibility of
MOSFETs for low dose deliveries was 26.6, 50.4 and 18.1% in 150 kVp, 180 kVp and 6 MV
beams, respectively. Gafchromic film has good precision at low doses. The reproducibility
of EBT2 was 1.0% for beam energy 6 MV. For 150 and 180 kVp, the uncertainty of XR-QA2
film was 3.1 and 3.0%, respectively. For exposures above 3 cGy, the accuracy of XR-QA2 is
within 5% for measurements made within 150 and 180 kVp beams. EBT2 Gafchromic film
overestimates the dose by approximately 20% in the peripheral regions of MV beams.
Despite the relatively large uncertainties for some dose measurements, the overall sec-
ondary cancer risk remains low.
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6.3 Conclusion
The risk of radiation induced second malignancies was assessed for healthy tissue lying
near the treatment field, taking into consideration radiation dose associated with planning
imaging (CT), pretreatment imaging (CBCT) and treatment. The risk of thyroid and con-
tralateral breast carcinoma from early stage breast radiotherapy and the risk of contralateral
testicular carcinoma from seminoma radiotherapy were investigated. The maximum surface
dose to the remaining testis, contralateral breast and thyroid was 0.68, 4.96 and 1.0 Gy,
respectively. With gonadal shielding fitted to reduce the testicular dose, the accumulative
risk of radiation induced testicular cancer was found to be 0.4% and 0.2% for dogleg and
paraaortic treatment fields, respectively. The accumulative risk of radiation induced second
malignancies to the CB was found to be 1.1 - 1.4%, depending on the treatment technique
used. Dose conformity using physical wedges resulted in the highest CB dose and therefore
the highest risk. The resulting accumulative risk of thyroid cancer from radiotherapy treat-
ment for early stage breast carcinoma was found to be minimal, 0.2%. Despite the minor
risk of radiation induced carcinoma to the assessed radiosensitive tissues, when considering
possible treatment techniques and/or introducing pretreatment imaging protocols, the dose
to the normal tissue should be kept as low as reasonably achievable.
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